S C I E N C E L I F E 05-06 March 2013 Hilton Zurich Airport Hotel Conference Guide ORGANISERS www.sachsforum.com SUPPORTING ORGANISATIONS E U R O P E A N for PARTNERING & INVESTING PRESENTING COMPANIES EUROPEAN LIFE SCIENCE CEO FORUM SPEAKERS C E O F O R U M WELCOME 6th Annual WELCOME t back :: next u Welcome Sachs Associates are delighted to welcome you to the: 6th Annual 5th - 6th March 2013 Hilton Zurich Airport Hotel This exclusive and transactional event compliments our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their current and future partnering strategies through thought-provoking case studies. General Information вЂў The registration desk is open from 8am on both days although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session. вЂў Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk. вЂў The one-to-one meetings are being held in the La Place A and B. Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance. SUPPORTING ORGANISATIONS This yearвЂ™s programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving Finance and M&A market, Partnering activity, Vaccines, Oncology and Biomedical Investment, and includes special keynote speeches, providing an expert outlook on EuropeвЂ™s Biotech industry. In addition, the event holds exclusive Partnering Workshop Presentations and more than 60 exclusive company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise finance and/or find partners. PRESENTING COMPANIES Sachs Associates are delighted to welcome you to the 6th Annual European Life Science CEO Forum for Partnering & Investing. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. SPEAKERS European Life Science CEO Forum for Partnering & Investing Request for Presentations ORGANISERS Please use the agenda to mark off presentations that you are interested in and email your request to zoe@sachsforum.com after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference. WELCOME t back :: next u Events Diary For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Zoe Harris on zoe@sachsforum.com SPEAKERS Annual CANCER BIO PARTNERING FORUM Promoting Public & Private Sector, Collaboration & Investment in Drug Development 21st - 22nd May 2013 вЂў The Westin Copley Place вЂў Boston 13th Annual Biotech in Europe Investor Forum 30th September - 1st October 2013 вЂў Zurich Back for its 13th year, the Biotech in Europe Investor Forum will once again be held in Zurich. Featuring our core sponsors, an audience of over 400 investors, analysts & media, with presenting opportunities for over 60 public and private companies and panel themes including Finance & Investment, Partnering and more, this event is a must for all key players in the Biotech and Pharma industry. View last yearвЂ™s event at: www.sachsforum.com/zurich12/index.html ORGANISERS The forum will be an excellent platform for companies to raise their profile by promoting their interests to the larger financial community. Facilitated by its successful one-on-one meeting system and networking receptions, the event will help build strong and meaningful business relationships through face to face communication, and promises to be a great opportunity to meet emerging companies, leading global investors, analysts, advisors and Big Pharma representatives. Panel discussions with participation from industry leaders and experts in their sector, makes the Biotech In Europe Investor Forum an excellent way to gain insight and keep up to date with partnering and investment and current industry trends. SUPPORTING ORGANISATIONS Sachs Cancer Bio Partnering Forum will cover the following topics in the program: вЂў Big Pharma Approach to Innovation вЂў Cancer Stem Cells вЂў Cancer Tech вЂ“ Device, Diagnostics & Image Technologies вЂў Deal Making and Investment вЂў Immunotherapies & Cancer Vaccines вЂў Israel Bio-Med вЂў Personalised Oncology and Diagnostics вЂў Public-Private Partnerships вЂў Translational Research вЂ“ Advances & Directions PRESENTING COMPANIES The Sachs Cancer Bio Partnering Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 300 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of presentations by research institutes, patient advocacy groups, pharmaceutical companies on partnering and biotechвЂ™s seeking licensing/investment.The Forum will feature an online one-to-one meeting system with designated meeting space available to all attendees. WELCOME Speakers Alexandra Goll, General Partner, TVM Capital Prior to her affiliation with TVM Capital, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd. in Basel. She had been involved in clinical development and managing commercialization strategies of products such as NeupogenВ® (under an agreement with Amgen), HividВ®, CymeveneВ® and ValcyteВ®. Dr. Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was also honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine. Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry and venture capital. Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The company used a novel drug discovery technology developed in several academic labs, including EliseevвЂ™s group in Buffalo. He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos was acquired by Amgen in 2007 for $300 million. Andrew Slade, President, Menarini Pharma Dr. Andrew Slade is President of Menarini Biotech. In this role, he is responsible for the biotechnology R&D and manufacturing undertaken by Menarini and in the in-licensing of biotech products. Dr. Slade was previously Head of Manufacturing for a major Biologics company and before that was employed by GSK in various senior product development and operational roles. He studied biochemistry and enzymology. SUPPORTING ORGANISATIONS Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous deals with portfolio companies in the US and Europe. PRESENTING COMPANIES Alexey Eliseev, Managing Director, Maxwell Biotech Venture Fund SPEAKERS Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Sweden), Biovertis AG (Vienna, Austria) and Cerenis Therapeutics (Toulouse, France and Ann Arbor, MI). She also represents the interests of TVM Capital with Addex Pharmaceuticals SA (Geneva, Switzerland), MediGene AG (Martinsried), Newron Pharmaceuticals SpA, (Bresso, Italy) and Wilex AG (Munich, Germany). t back :: next u Alexandra joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital life science investments. She initiated TVM CapitalвЂ™s lead investment in Actelion Ltd (Allschwil, Switzerland) and led the firmвЂ™s successful investments in Idenix Pharmaceuticals, Inc. sold to Novartis, and Pharmasset Inc. which was sold to Gilead Sciences вЂ“ TVM Capital acted as a lead investor in both cases. She also initiated and managed the investment in EUSA Pharma Ltd., recently sold to Jazz Pharmaceuticals Inc. ORGANISERS WELCOME Speakers Anja Konig, Managing Partner in Basel, Novartis Venture Fund Anthony Hartley is a Managing Director in UBS Investment BankвЂ™s Global Healthcare Group. He is based in London and mainly focuses on pharmaceutical and biotechnology companies in Europe. SPEAKERS Anthony Hartley, Managing Director, Investement Banking, USB t back :: next u Dr Anja Konig is active in Switzerland and Europe and also responsible for expanding the fundвЂ™s presence to Asia Pacific. Prior to joining Novartis she was an Associate Partner at McKinsey and Company, a global consultancy, where she worked with companies in health care in the US, Europe and Emerging Markets. Anja KГ¶nig is a scientist by training and holds a PhD in physics from Cornell University. Anja serves on the boards of Bicycle, Covagen, Diagnoplex, Heptares, and Nabriva, and works with Destiny, MerLion, Neomics, PharmAbcine, Polyphor, Qurient Therapeutics and S*BIO. Anthony joined UBS in 2012 from Morgan Stanley and has spent 12 years in healthcare investment banking, predominantly advising healthcare clients with a primary focus on the pharmaceutical and biopharma sectors. Anthony received a Doctorate (D.Phil) in Pharmacology from The University of Oxford, and an MBA (Distinction) from Manchester Business School. Prior to his career in investment banking, Anthony spent a total of 7 years in the pharmaceutical industry working in a variety of research and commercial roles at Pfizer, GSK and AstraZeneca Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, Addex, Orexo, NovusPharma (then sold to CTI), Movetis (then sold to Shire) and Stentys, which went public respectively on the ZГјrich stock exchange, the Stockholm stock exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aventis). He has also invested in and is a board member of private companies MD Start, CoAxia, EOS, Mainstay and Recor. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. PRESENTING COMPANIES Antoine Papiernik, Managing Partner, Sofinnova Partners Arin Ghasparian, CEO, Virometix Ben Cons, Vice President, Corporate Development, Quintiles Ben Cons PhD, Global Vice President Quintiles Corporate Development structures and delivers managed partnerships with pharmaceutical and biotechnology industries. SUPPORTING ORGANISATIONS Dr Arin Ghasparian co-invented and developed Virometix Synthetic Virus-Like Particle technology. Before becoming VirometixвЂ™ CEO in 2012, he served as Chief Scientific Officer and was responsible for all R&D activites of company, established R&D partnerships and brought Virometix programs from research to proof-of-concept in animals. Prior to founding Virometix he worked as a researcher at the University of Zurich, where he developed new approaches to vaccine design. He has a background in organic chemistry and received a Doctorate in biochemistry from the University of Zurich. He has also participated in several entrepreneurship and business courses to expand his knowledge base in this area. An innovative team leader, he is adept in developing partnership solutions between companies that realize value for all parties. Dr. Cons joined Quintiles in 1996, bringing his expertise in pharmaceutical drug development and commercialization to drive corporate development goals. Early on in his career, Dr. Cons expanded his research experience in molecular pharmacology through a position in drug development for Schering AG. Later, at Glaxo Wellcome, he developed an expertise in marketing and business development. ORGANISERS Educated in the U.K., Dr. Cons acquired a bachelorвЂ™s degree in biological sciences with honors from Portsmouth Polytechnic, and then continued his studies to earn a doctorate in molecular pharmacology within the physiology and pharmacology department of Southampton University. WELCOME Speakers Carles DomГЁnech, Founder & CEO, Ability Pharmaceuticals Carles DomГЁnech obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs. Carles has also 4 yearsвЂ™ experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona EmprГЁn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments. SPEAKERS Carles has 15 years international experience in business development and licensing in the pharmaceutical industry. He held senior positions at the Barcelona pharmaceutical companies Almirall, SA (1992-2003, Manager and Head, Business Development and Licensing) and Lacer, SA (2005-2007, Director, Business Development and Licensing). t back :: next u Carles started developing his career in cancer research at CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992). In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009. Charles Wilson serves as the Global Head of Strategic Alliances, leading a group responsible for research partnering at Novartis. Partnering efforts include academic relationships to understand disease processes, biotech collaborations to access drug discovery technologies, and in-licensing of compounds prior to clinical proof-of-concept. Prior to joining Novartis, Chuck founded and led Archemix, a company focused on aptamer therapeutics. Responsible initially as its Chief Technology Officer for developing the companyвЂ™s technology platform and managing its drug discovery efforts, he moved into a business role focused on partnering with pharma and biotech companies. Before moving into industry, Chuck was a professor in the Department of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz where his group determined the first x-ray structures of aptamers bound to their targets. Formally trained in structural biology and molecular biology, Chuck received his PhD from UCSF and his post-doctoral training at MGH. Chris Britten is the Managing Director of Vantage Life Science. He has a scientific background, a PhD in biochemistry and an MBA. Chris has gained huge experience and contacts in the Life Sciences market having negotiated a variety of acquisitions, licences, divestments and strategic alliances with partners around the world. Chris Janssen, Director of Science and Innovation, Biomedical Cluster, Skolkovo Foundation ORGANISERS Starting with a career in BioMedical research, Chris Janssen has extensive experience in science development. After spending some years in academia, Chris moved on to business, founding a biotech company. Following on from success in research and business, he has led national development efforts in BioMedical technologies, lastly as director for the national development program for quantitative biology and medicine at ScotlandвЂ™s national academy, the Royal Society of Edinburgh, with particular emphasis on commercialisation and business integration. Chris has participated in governmental and parliamentary advisory groups, and in oversight groups at the National Health Service. His achievements include creating access for business to integrated health care and science information, focusing public-private partnership support funding for development of cutting edge science research in SMEs, and setting up collaborative networks between health care, academia, and industry. Since mid-2011 Chris has held the position of Director for Science & Innovation at the BioMedical Technologies Cluster Skolkovo, Russia. His remits include setting priority thematic areas for support, overseeing the ClusterвЂ™s part in the due diligence process for grants, working with major multi-nationals, and facilitating the creation of appropriate infrastructure for the ClusterвЂ™s participants. Chris sees his primary goals as identifying excellent science in the biomedical area in Russia, and facilitating its commercialisation, bringing cutting edge start-up companies to Russia, and assisting in creating the right infrastructure to necessary for successful growth of biomed business in Russia. SUPPORTING ORGANISATIONS Chris Britten, Managing Director, Vantage Life Sciences PRESENTING COMPANIES Charles Wilson, Vice Presdient, Global Head of Strategic Alliances, Novartis Institute for BioMedical Research, Inc. WELCOME Speakers Christina Takke, Partner, Forbian Capital Partners SPEAKERS Daniel Bach, Associate, Life Sciences, Index Venture t back :: next u Christina Takke holds a PhD in Molecular Biology from the University of Cologne. She specialized in Functional Genomics and focused on early embryonic development. Christina completed a PhD thesis on cell-cell interactions during zebra fish neurogenesis and somitogenesis. After her internationally oriented academic career, she worked at Bio-Gen-Tec, NRW, a German Governmental Agency as a Business Consultant. She joined the Life Science team in 2000 and has been responsible for conducting scientific and clinical due diligence investigations and providing scientific support to our portfolio companies. Furthermore she holds non-executive board positions with Pieris AG, arGEN-X BV and Amakem NV. Christina acts as ForbionвЂ™s Compliance Officer. Daniel Bach is an Associate in the life sciences team, having joined the firm in 2007. DaniвЂ™s areas of interest range from metabolic diseases to virology and prior to joining Index, Dani was conducting research at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked on the complex interactions between human immunodeficiency virus (HIV) and the human immune system. Dani holds a Master in Start-up Business Administration and a PhD in Molecular Biology from the Universitat de Barcelona. Daniel Dornbusch has served in multiple management roles at pharmaceutical, biotechnology, and diagnostics companies including Novartis, Genentech, and Genzyme. Daniel has spent over 15 years in the biopharmaceutical and diagnostics industry in various roles including business development, sales, marketing, corporate development, and commercial management. Daniel joined Nodality from Novartis Diagnostics where he held the position of Commercial Director of Latin America. Daniel joined Novartis in business development where he completed numerous business development transactions. Before Novartis, Daniel held roles in business development at Cerimon Pharmaceuticals Inc., led business development and sales for an Amerisource Bergen company, and led a marketing team at Genentech, Inc. Daniel began his career at the Genzyme Corporation and served in numerous roles including in business development, product management, and corporate development. Daniel received his B.A. in Biology and English from Cornell University, M.A. from Tufts University School of Medicine and Emerson College, and M.B.A. from the Harvard Business School. Dr Daniel Teper is the founder and currently the Chief Executive Officer of Immune and has been such since 2010. From 2005 to 2010, Dr. Teper was a New York-based Managing Partner and Head of North America at Bionest Partners,a Global Management Consulting firm, where he advised pharmaceutical and public biotechnology companies with respect to Corporate Strategy, Business Development, Mergers & Acquisitions, New Product Development and Commercialization. he had previously been a New York based Partner at ISO Healththcare Consulting, later acquired by Monitor Group. Dr.Teper started his career in 1984 at at Novartis in Base, CH and then in the United States where he help growing management responsibilities in sales, marketing and eventually as Head of New Product Development for Cardiovascular Products. Dr.Teper returned to Europe as Senior Vice President and Head of Marketing & Sales at Glaxo France and then as President and Chief Operating Officer of Laboratoires Delagrange which was acquired by Synthelabo (now Sanofi). He tehn founded and was the CEO of WINTEC Pharma, a specialty Pharmaceutical company, which he sold part to Norgine (UK) and part to Galephar (Belgium). Dr. Teper then joined HAVAS-EURO RSCG Healthcare Worldwide, as President, Global, where expanded Euro Rscg operations internationally and advised pharmaceutical companies on Global Launches of major new drugs. Dr. Teper co-founded Novagali (NYSE Euronext: NOVA), a pharmaceutical company specializing in ophthalmology and which was recently acquired by JapanвЂ™s Santen. Dr. Teper holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD where he was a J.Salomon scholar. SUPPORTING ORGANISATIONS Daniel Teper CEO, Immune Pharmaceuticals PRESENTING COMPANIES Daniel Dornbusch, VP BD, Nodality Inc. ORGANISERS WELCOME Speakers Donald McCaffrey, President and CEO, Resverlogix Corp. SPEAKERS DonвЂ™s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Mount Royal College, Alberta ChildrenвЂ™s Hospital, Education Matters, and Calgary Urban Project Society Literacy Program. t back :: next u Donald McCaffrey is Co-Founder, President, & CEO of Resverlogix Corp. He has over 30 years of experience in drug discovery & development, and international conference and tradeshow management across multiple industries, including biotechnology. Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed company, including raising over $185 million. In addition to garnering appropriate financing for ResverlogixвЂ™s aggressive development plan, Don has strategically directed the Company in its discussions with top global pharmaceutical companies, while creating new therapeutic markets for its key technology platforms. DonвЂ™s expertise in corporate operations has attracted an international team of R&D experts to Resverlogix. This scientific and operational expertise has pioneered RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease. Under his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award. Einat Zisman, CEO, Bio-Holdings Ltd. Enrico Bastianelli, CEO, Bone Therapeutics Since June 2006, he is Chief Executive Officer of Bone Therapeutics; a leading international biotechnlology company specialized in the treatment of osteo-articular diseases using cell therapy. Erich Mohr, Chairman & Chief Executive Officer, MedGenesis Therapeutix Inc. Erich Mohr, Ph.D., R.Psych. founded MedGenesis Therapeutix Inc. in 2006. He is an internationally recognized expert in experimental therapeutics for central nervous system disorders and has served as the principal investigator on numerous clinical trials. He has chaired and/or served on several regulatory advisory panels and has a lengthy history of service on medical advisory boards for several of the worldвЂ™s largest pharmaceutical firms as well as a number of biotechnology companies. SUPPORTING ORGANISATIONS Dr Bastianelli has a long standing experience in pharmaceutical industry in fields as broad as Sales & Marketing, R&D, Licensing, Corporate Development and Strategy. His career started in the Pathology Department of the Erasme University Hospital in Belgium. Then he joined Procter & Gamble Pharmaceuticals in 1996, where he was involved in the marketing of ethical and over-the-counter drugs in the field of bone diseases. In 1999, he became a Consultant for McKinsey & Co, where he was involved in strategic and organizational missions for major pharmaceutical as well as biotechnology companies all over Europe. From its creation in 2002 until mid-2006, Dr Bastianelli worked as VP Corporate Development for ProSkelia, the spin-out of Aventis focused on bone diseases and hormone disorders (which then became ProStrakan, after the merger with Strakan, a Scottish pharmaceutical company). PRESENTING COMPANIES Dr Einat Zisman is the CEO of Hadasit Medical Research Services & Development Ltd., the technology transfer company and commercial arm of Hadassah Medical Organization in Jerusalem, Israel. Prior to joining Hadasit, Dr. Zisman served as the Chief Business Officer of Yeda, the technology transfer arm of the Weizmann Institute of Science. Dr. Zisman also served at a range of senior positions in the Israeli bio-tech industry, among them managing projects, managing research and overall development and promotion of projects that originated in the academia. Dr. Zisman holds an MBA from the Marshall Business School, University of Southern California, USA, a PhD in Immunology from the Weizmann Institute of Science and a B.Pharm degree from the Hebrew University of Jerusalem. Dr. ZismanвЂ™s expertise is in building value via licensing, partnering, initiating start-ups, financing and marketing of early stage intellectual property. In 1995, Dr. Mohr founded CroMedica, a Canadian based global, full service CRO with a strong focus on Central Nervous System Disorders which became a global corporation with over 550 employees and offices in 5 continents. In 2002, the company merged with PRA International where he served as Chief Scientific Officer for a period of almost 4 years. In 2004 PRA International achieved listing on Nasdaq (PRAI) and is now one of the top 5 CROвЂ™s in the world. Dr. Mohr earned his doctorate in neuropsychology in 1982 and master of science degree in neuropsychology in 1980, both from the University of Victoria, British Columbia, Canada and obtained his undergraduate education at The University of the Pacific, Stockton, California, USA. He is the recipient of a number of academic and industry awards, among them the Legacy Award (Alumni of the Year) from the University of Victoria. ORGANISERS Dr. Mohr was trained at the National Institutes of Health in Bethesda, Maryland and was also on staff at the NIH for a period of four years. He held an academic appointment as Professor of Medicine and Psychology at the University of Ottawa School of Medicine until 2002 and is credited with over 150 publications, books, book chapters and abstracts WELCOME Speakers Esteban Pombo Villar, Chief Operations Officer, Oxford BioTherapeutics AG Florian SchГ¶del, CEO, Phillimmune LLC Florian SchГ¶del is the founder of Philimmune LLC, a consulting firm which provides strategic advice in the development of biologics, vaccines and pharmaceuticals. Florian has > 20 years of successful experience in leading teams in the development of vaccines and biologics in the pharmaceutical and biotech industry and in academia. PRESENTING COMPANIES Dr Fintan Walton is the Founder and CEO of PharmaVentures. He was educated at the University of Michigan (US) and Trinity College (Dublin, Ireland), and subsequently he gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992). As an entrepreneur, Dr Walton co-founded CONNECT Pharma in 1992, a company focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making including strategic alliances, Mergers & Acquisitions and equity financing. In 1997 the company became PharmaVentures. His company has worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 37 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. His clients have also included major banks, investment/merchant banks, and private equity and venture capital groups. Although FintanвЂ™s main focus is his role as Chief Executive Officer of PharmaVentures, he actively participates in many consultancy assignments. SPEAKERS Fintan Walton, CEO and Founder, PharmaVentures t back :: next u Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry. His passion is preventative medicine and the use of modern science and technology for the improvement of public health вЂ“ especially in the development of preventative and therapeutic vaccines and biologics. He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national regulatory agencies. Florian has led the clinical teams responsible for several successful vaccine filings. A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories before he founded Philimmune. Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at the LMU and at the Biodesign Center of the ASU. FlorianвЂ™s research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and typhoid. SUPPORTING ORGANISATIONS Florian has a track record in running scientific and operational organizations, in business and strategic planning, for forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical development. Florian joined Merck Research Laboratories in 1996 as Director Clinical Vaccine Research leading EU vaccine clinical trials and the clinical development of rotavirus vaccines and varicella, measles, mumps, rubella combination and shingles vaccines. As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines. ORGANISERS WELCOME Speakers Guillaume Vignon, Director Business Development Oncology, Global Licensing & Business Development, Merck Serono Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France. SPEAKERS Before his positions as global transactor, Guillaume served as inhouse consultant for Merck KGaA, Damstadt, Germany, leading several assignments in the field of management strategy, implementation, commercial operations BU Oncology, and business planning BU Oncology. t back :: next u Mr Guillaume Vignon is Director of Business Development Oncology with Merck Serono, responsible for designing deal structures and negotiating the terms of complex strategic transactions in the field of Oncology. Prior to this position, Guillaume was Director of Strategic Transactions, responsible for partnerships of pre-clinical stage assets, enabling technologies, and companion diagnostics. During his career at Merck Serono, Guillaume closed successfully several key partnerships for Merck Serono in the field of Oncology, Companion diagnostic, and Antibody discovery. Hampus Hillerstrom, Executive VP and Chief Business Officer, Neurophage Pharmaceuticals PRESENTING COMPANIES Hampus Hillerstrom is a co-founder and board member of NeuroPhage and serves as Executive Vice President and Chief Business Officer. Previously, he spent 3 years as an associate at leading European biotech venture capital firm HealthCap where he participated in a large number of investment transactions including several IPOs. More recently Mr. Hillerstrom spearheaded a project at AstraZeneca to evaluate decision-making leading to Phase III clinical trials. Previously Mr. Hillerstrom was a partner in the Zurich-based consulting boutique Venture Valuation specialized in the assessment and valuation of biotech companies. For a year prior to that he worked in mergers and acquisitions at the investment bank Lazard in the pharmaceutical and chemicals industry teams. Mr. Hillerstrom holds a Masters in Economics and Finance from the University of St. Gallen, an MBA from Harvard Business School, and an MSc in Health Sciences and Technology from MIT/Harvard Medical School (HST). Igor Pivovarov, CEO, HemaCore LLC Igor Pivovarov is CEO & Co-Founder of HemaCore and Co-Founder & Member of Board of several companies. HemaCore is a biotech company which develops medical devices and assays for hematology. The Company was invested in by RUSNANO to bring it to the market. Thrombodynamics is a new global assay for monitoring and prognosis of blood coagulation disorders and finding out risks of bleeding and thrombosis. Irena Melnikova, Managing Director Russia, Burrill & Company Irena Melnikova joined Burrill & Company in October 2012 as Managing Director, Russia. Prior to joining Burrill & Company, she served as Director of Strategy and External Innovation at Sanofi. Previously, Irena was a Principal in the Life Science team of TVM Capital, a global venture capital firm. At TVM, she was involved in deal origination and new investment opportunity evaluation and actively participated in the management of TVM Capital investments in the United States. Prior to TVM Capital, she was a member of the biopharma investment banking team at Leerink Swann. She also produced and launched a new series of syndicated reports for the firm. Entitled Future in Focus, these reports provided clients with insight and analysis of business and technology issues shaping corporate and R&D strategies, pipelines and alliances. Irena has published over 20 manuscripts in peer-reviewed journals and is a regular contributor to the вЂњAnalyst CouchвЂќ section of Nature Reviews in Drug Discovery magazine. She holds an M.S. in chemical engineering from the Mendeleev University of Chemical Technology of Russia and a Ph.D. in molecular medicine/molecular biology from the University of Texas. ORGANISERS Prior to Leerink Swann, Irena was a Research Manager at Life Science Insights, a subsidiary of IDC, the leading technology market research company. As a project leader at TransForm Pharmaceuticals (acquired by Johnson & Johnson), she was responsible for running several programs, including Engineered Tissue Constructs, funded by DARPA, and Amyloidoses. SUPPORTING ORGANISATIONS Igor has 6 years basic research experience in biophysics, mathematical modeling. 15 years business experience as an engineer, CTO, CMO, CEO and he has raised over $22M in investments. WELCOME Speakers Jakob Knudsen, CEO, ViroGates SPEAKERS Jason Rushton, Head of Life Sciences Advisory Initiative, Deloitte t back :: next u Jakob Knudsen assumed his role as CEO of ViroGates in April 2011. Jakob was previously CCO & CFO of Egalet Ltd. a Danish based biotech company focusing on development of pain products. Jakob oversaw all commercial operations including IP and Financing, and was responsible for entering into multiple commercial collaborations (licensing and feasibility stage agreements). Prior to this Jakob was heading the Corporate Business Development function at ALK-AbellГі A/S, a Danish biopharmaceutical company. Jakob was responsible for ALKвЂ™s licensing and M&A deals. Before this Jakob held positions within sales and marketing with the company. Jakob is a lawyer by training and he also holds an MBA from Imperial College, UK. Jason leads the life science focus of Deloitte Corporate Finance in Switzerland. He has 20 years of experience in the pharmaceutical sector spanning R&D, management consulting and venture capital. Jason began his career in drug discovery with Eli Lilly and then moved to PA Consulting Group where he advised pharmaceutical/biotech clients in technical, commercial due diligence and financial transactions. For 10 years Jason was a venture capital investor with direct involvement in completing over 30 private life science transactions latterly with the venture capital fund of Nestle. Jeroen Tonnaer, xecutive Director, Head European External Scientific Affairs, Worldwide Licensing, MSD Jeroen Tonnaer PhD obtained an MSc in biology from the University of Nijmegen and a PhD in pharmacology from the Medical Faculty (Rudolf Magnus Institute for Pharmacology) of the University of Utrecht. Part of his PhD work was performed at the INSERM laboratories in Paris. Following Schering-PloughвЂ™s acquisition by Merck, Jeroen joined MerckвЂ™s Worldwide Licensing organization in February 2010 to become head of the European External Scientific Affairs team. Since then this team has been the driver in the identification and execution of several major licensing and partnering deals including those with Ablynx, AiCuris and Delphi Genetics. Johanna Holldack, CEO, Telormedix S.A. Johanna Holidack has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene and Borean Pharma. SUPPORTING ORGANISATIONS Jeroen joined Organon as a neuroscientist in 1982. As Assistant-Manager of the CNS Program he was responsible for the pre/early clinical development of SAPHRISВ®/SYCRESTВ® (asenapine). He held further positions as Head DMPK, Executive Director Toxicology, Executive Director Global Research Alliances and, upon acquisition of Organon by Schering-Plough, Head Discovery Collaborations Europe. In the latter role he led the team that facilitated licensing and collaborative efforts for the Schering-Plough scientists based in Europe, focused personally on the WomenвЂ™s Health field and was the business liaison for Schering-Plough in the consortium TI Pharma. PRESENTING COMPANIES Jason has been a board member of a number of biotech companies and has firsthand experience of business development and licensing. Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School. ORGANISERS WELCOME Speakers John Cullity Principal, Torreya Partners Jonathan Garen, Executive Director Business Development, Forest Laboratories Jonathan Garen is an Executive Director of Business Development at Forest Laboratories, Inc., where he has worked since 2003. His responsibilities include the identification, evaluation, and negotiation of transactions for new business opportunities in a wide range of therapeutic areas and stages of development, including licensing and acquisitions in the fields of neurology, inflammation, oncology and metabolic diseases. Prior to Forest, Jonathan was a Director in the Global Licensing department at Pharmacia Corporation. Jonathan was a founder and Vice President of TechEx, an online licensing exchange for early stage opportunities, and was a Licensing Associate at the technology licensing office of Yale University. Jonathan earned his Master of Environmental Sciences from Yale University and his Bachelor of Science in Physics from the Massachusetts Institute of Technology. Jorn Aldag joined uniQureвЂ™s predecessor company AMT in October 2009. He has led uniQureвЂ™s corporate development including the build-up of its gene therapy pipeline, the marketing authorization process at EMA for Glybera, and several dilutive and non-dilutive financing transactions. Before joining uniQure he was instrumental in building Evotec AG (FSE: EVT), from 1997 to 2000 as CFO and from 2001 to 2009 as President and CEO. EVT designed and implemented a cutting edge small molecule technology platform, became a leader in drug discovery services and developed a promising CNS pipeline. Prior to Evotec, JГ¶rn Aldag served in various financial management positions at MAN AG, and as Business Director at Treuhandanstalt, the agency responsible for privatizing the East German economy after the German reunification. JГ¶rn Aldag is Chairman of Molecular Partners AG, Zurich, Switzerland, and a member of the Board of Directors of the DESERTEC Foundation, Hamburg, Germany. He holds business degrees from the Harvard Business School and the European Business School. SUPPORTING ORGANISATIONS JГ¶rn Aldag, CEO, uniQure PRESENTING COMPANIES John Trizzino B.S., M.B.A., is a senior executive with more than 25 years of experience advancing strategic initiatives for publicly traded biotechnology companies, primarily within the vaccine market. Prior to joining Immunovaccine, he was the Senior Vice President at Novavax Inc., where he provided strategic direction and successfully negotiated profitable joint venture and licensing agreements, including a $179M BARDA contract. Prior to joining Novavax, Mr. Trizzino held senior executive positions at MedImmune Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of GlaxoSmithKline Inc. He began his extensive career in vaccines at Henry Schein Inc. leading commercial marketing efforts and executing a series of successful commercialization and distribution agreements. Mr. Trizzino is a graduate of Long Island University and received his masterвЂ™s degree in business administration from New York UniversityвЂ™s Leonard N. Stern School of Business. SPEAKERS John Trizzino, CEO, ImmunoVaccine, Inc. t back :: next u John Cullity works at the New York office of Torreya Partners, a life sciences advisory firm providing services in M&A, licensing, and corporate finance. Previously he was at Sanofi Aventis where he coordinated $3 billion transactions in oncology and diabetes. John led Sanofi AventisвЂ™ strategic pricing department managing the $15 billion portfolio, and placing valuations on the pipeline. He was previously at Schering-Plough in strategic pricing and health economics. John has also worked for AT Kearney, World Bank, WHO and as an internist in UK and Australia. He holds MBA Wharton, MSc (Econs) from LSE, Medical Boards from Royal College of Physicians UK, and medical degree from University of Western Australia. ORGANISERS WELCOME Speakers Julia Sardaryan, Head of Business Development, OCT Clinical Trials Julia Sardaryan graduated from St-Petersburg State University in 2007. Julia holds a masters degree in English Linguistics, Translation. Julia started her career in pharmaceutical business at OCT in 2007. Through the years she has demonstrated career development being Clinical Trials Coordinator, Business Development Manager and then Director of Business Development at OCT. Julian is co-founder and CEO of Covagen. After his studies in molecular biology and biochemistry at ETH Zurich, Julian Bertschinger joined the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences ETH Zurich as a Ph.D. student. There he co-invented Covalent DNA Display technology. After obtaining his Ph.D. in May 2005, he continued developing Covalent DNA Display as a postdoctoral fellow in Prof. Dario NeriвЂ™s group. In June 2006, Julian Bertschinger was selected from more than 100 applicants as one of the winners of the Venture Leaders Prize founded by the Gebert RГјf Stiftung. This enabled him to join a training program in the Boston area (USA) with a course in entrepreneurship at Babson College. PRESENTING COMPANIES Julian Bertschinger, CEO and Co-Founder, Covagen AG SPEAKERS OCT is an experienced full-service CRO successfully working in Russia, Ukraine, Belarus, Bulgaria, Latvia, Lithuania, Estonia since 2005. OCT provides the full-scale range of services to pharmaceutical, biotechnology and medical device companies. OCT is experienced in a wide range of therapeutic areas (oncology, neurology, cardiology, autoimmune disorders, pulmonology, gastroenterology, endocrinology, etc.); in phase I-IV studies, bioequivalence trials, pre-clinical studies. OCT has a record of studies with drugs, which were approved by FDA and EMEA afterwards; some of the trials were conducted in the Russian Federation exclusively. t back :: next u As Director of Business Development, Julia is responsible for new business opportunities assessment and management; she supervises OCTвЂ™s advertising, client relations and budget negotiations. She manages development of new relations with clients from all over the world. Ms. Sardaryan has dedicated much of her career to attracting pharmaceutical companies all over the world to conduct clinical trials in Russia, CIS and CEE region. Julia knows the specifics and challenges of conducting clinical trials in this region. Katya Smirnyagina, Venture Partner, Capricorn Ventures Kieran Murphy, President & CEO, GE Healthcare Life Sciences Kieran Murphy joined GE in April 2008 as a result of the acquisition of Whatman plc where he had served as CEO since early 2007. Following the acquisition he held a number of commercial roles before being appointed CEO of the Life Sciences business in early 2011. SUPPORTING ORGANISATIONS Dr Ekaterina (Katya) Smirnyagina PhD in Cellular & Molecular Biology (University of Wisconsin-Madison, USA), BS in Biochemistry (Lomonosov Moscow State University, Russia). Katya completed her scientific training at the Stanford University School of Medicine, then worked in management consulting and biotech business development. In 2002-12 she was with Alta Partners, a healthcare focused venture capital fund in San Francisco, CA. Prior to his position in Whatman, Kieran held a number of CEO positions in UK Biotechnology businesses including Adprotech, ML Laboratories and Innovata plc. He has been involved in the life sciences industry since joining Janssen Pharmaceutical in 1989. He served as CEO at Mallinckrodt, Vericore and Novartis Animal Vaccines. Born in Cork, Ireland, he is a graduate of University College Dublin and The University of Manchester Institute of Science and Technology. ORGANISERS WELCOME Speakers Kieran Rooney, CBO, Amakem NV Dr Kieran Rooney joined Amakem NV as Chief Business Officer in 2012. Over the past 6 years he has provided commercial and transactional consulting support to over 30 pharma/biotech companies and life sciences investors through the consultancy firm, Halo BioConsulting Ltd. Prior to founding Halo in 2007, he was a Consultant to the UK Government, supporting commercial activities across a portfolio of UK-based life science companies. SPEAKERS t back :: next u He has in over 25 years experience in the pharma/biotech space, having held drug discovery R&D, clinical, commercial and Board positions across a diverse range of organizations from multinational pharmas to biotech and pharmaceutical service organizations. He held senior commercial roles at Pharmaceutical Profiles Ltd, Pharsight Corporation and F2G Ltd and led commercial activities at MDS Pharma in Europe. A pharmacist by profession, he holds a degree in Pharmacy, a Ph.D. in neuropharmacology and began his career in CNS drug research. Konstantinos Alevizopoulous, CEO, APIM Therapeutics AS PRESENTING COMPANIES Konstantinos Alevizopoulous has thirteen years experience in the development and commercialization of therapeutic, diagnostic and medical device products in the biomedical sector. Since 2010, he has served as the Chief Executive Officer of APIM Therapeutics AS, a venture-capital financed oncology biotech (Norway). He is also a Partner of Ventac Partners, an international business development & consulting corporation. Other important past positions include: Chief Scientific Officer of Gerolymatos International SA (GR), Chief Executive Officer of Medexis SA (GR), Head of Preclinical R & D of Biovista Inc. (US) and Head of R & D of Apotech Corporation (CH). Dr. Alevizopoulos consults for several biotech companies, academic institutes and government associations; he is also a co-founder of Casigen Pharma (Hong Kong), Zestagen (CH), PharmaCellion (UK) and of the Hellenic Biotechnology Cluster (Greece). Dr. Alevizopoulos received his Biology degree from the University of Athens, Greece and his Ph.D. in Molecular Biology from the University of Lausanne, Switzerland. He has also conducted post-doctoral studies in the Swiss Institute of Experimental Cancer Research (Switzerland) and the Schering Plough Research Institute (USA) specializing in preclinical oncology research. Dr. Alevizopoulos is trained in European Patent Law (Robert Schuman University of Strasbourg, France). Laurent Choppe, Managing Partner, Life Sciences, Cukieman & Co. Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the Г‰cole Nationale VГ©tГ©rinaire dвЂ™Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD in Fontainebleau (France). He is married, father of 3 and lives in Lausanne (Switzerland). Lieven A De Smedt, CEO, ERA Biotech SA Lieven A De Smedt is an engineer in Agro and Food industries (WITH honors) at IHR-RUG, Gent, Belgium (вЂ�75-вЂ™80) and MBA (with honors) at KUL- Leuven, Belgium (вЂ�84-вЂ™85) and he holds a Masters in Finance (cum laude) at Tilburg University, Netherlands (вЂ™04-вЂ™05). SUPPORTING ORGANISATIONS Laurent Choppe is leading CLS since 2008 and brings an extensive international life science experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, biotechnology, nutraceuticals, animal health and direct-to-consumer markets. After a veterinary practice and a new venture management experience, he spent 10 years in Schering-Plough in various marketing and general management positions in France, Israel and Canada. He then served as international General Manager of BELLUS Health (ex-Neurochem NASDAQ & TSE), a Canadian biopharmaceutical company mainly involved in orphan drugs and AlzheimerвЂ™s disease. LievenвЂ™s work experience can be summarized as follows: At ERA Biotech SA as: CEO (Feb-11 вЂ“ YTD) and NED and interimCEO (2010) At Revolymer Ltd. as: Chief Business Officer (Sept-08 to 2010), CFO and Company Secretary (2005 to Sept-08) and Cofounder (inception in Oct 2005) Albemarle Corp (a $2.5 billion chemical and fine chemical global company), Global Business Manager (вЂ™93-вЂ™00) and Market Manager, Pharmaceutical Fine Chemicals (вЂ™89-вЂ™93) Amylum NV (became later Tate&Lyle, now Tereos), Market manager (вЂ�84-вЂ�89) Sopura SA (mid-size chemical company, supplying the food industry), Market manager (вЂ�82-вЂ™84) ORGANISERS InnoTune BVBA (Formerly ARS.21 BVBA), Jan 2000-Date, Founder and Managing Director WELCOME Speakers Lloyd Diamond, CEO, BONESUPPORT Lubor Gaal is the Head of Europe, Search and Evaluation, Strategic Transactions Group for Bristol-Myers Squibb, based at the UK headquarters in Uxbridge (London). He is responsible for licensing and acquisition of drug programs, assets or companies in support of the companyвЂ™s BioPharma strategy. Malcolm Weir, Founder, Director, CEO, Heptares Therapeutics Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as co-Founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997 and is on the Chemistry and Chemical Biology Advisory Boards at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 вЂ“ 2011. SUPPORTING ORGANISATIONS Lubor has extensive experience in evaluating and negotiating transactions with small and large companies, having worked in the U.S. and in Europe. Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d in France and CBO of Vectron Therapeutics AG in Germany. In the U.S., Lubor worked for Berlex Laboratories, where he was responsible for worldwide licensing for Cardiovascular and Neuroscience for Schering AG (now Bayer HealthCare AG). Before joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and execution. Lubor received his Ph.D. from the University of California at Berkeley and his B.Sc. in Neuroscience from the University of Sussex in Brighton in United Kingdom. PRESENTING COMPANIES Lubor Gaal, Head of Europe, Strategic Transactions Group, BMS SPEAKERS Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations. t back :: next u Lorenza CastellГіn, Health & Biotech Equity Analyst, Equity Development Ltd ORGANISERS WELCOME Speakers Mark Bleckmann, Director & Head of Finance, immatics biotechnologies Following degrees in business administration and philosophy, Mark Bleckmann started his career at IBM, where вЂ“ over the course of 9 years вЂ“ he held roles of escalating responsibilities in various finance and planning functions. In his last position at IBM he was Finance Manager of the Frankfurt office and one of EuropeвЂ™s largest outsourcing contracts at the time. Markus Hosang, General Partner, BioMedPartners AG Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Chief Scientific Officer of Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee. Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting SUPPORTING ORGANISATIONS He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular dieseases. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Okairos AG, Suppremol GmbH and Anergis SA (as interim Chairman of the Board). Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents. PRESENTING COMPANIES Markus is Managing Director, Novartis Venture Fund Markus Goebel started his career in the Health Care Industry in 1990. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters, partially in a ww alliance with Amgen. He joined Novartis in 2000 and first worked as global head Nervous System BD&L Pharma and later as global head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US. Previously he received an MD and a PhD from the Ludwig MaximilianвЂ™s University in Munich and an MBA from Henley Management College. Markus serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx, EraGen and Intellikine. SPEAKERS Markus Goebel, Managing Director in Basel, Novartis Venture Funds t back :: next u He joined immatics in 2008 where he is responsible for managing all finance matters and as well as other administrative functions of the company. In 2010 immatics successfully closed a C financing round, raising в‚¬54m. Dr Martina Kaufmann is founder and managing director of Martina Kaufmann Strategic Consulting offering individual solutions for personalized medicine. She is a pharmacist with scientific track record in molecular biology and >14 years of hands on experience in personalized medicine from a technology / diagnostic as well as from a pharmaceutical perspective across the lifecycle. She established and implemented consolidated project specific biomarker / diagnostic strategies for various oncology development projects in exploratory and full development, as well as for market adoption and lifecycle management of marketed targeted therapies/companion diagnostics, e.g. HerceptinВ®/HER2. She also has experience in molecular imaging agent development, enabled market entry of a microarray based protein profiling system in Europe and successfully launched a microarray based pharmacogenetic profiling system. ORGANISERS Dr. Kaufmann has a comprehensive, inter-divisional background with experience not only in drug development/translational medicine, molecular diagnostics, and molecular imaging, but also in marketing, sales, project management, and business development in biotech start-up as well as global pharmaceutical organizations. WELCOME Speakers Mette Kirstine Agger, Managing Partner, Lundbeck Ventures Neil Warma, President & CEO, Opexa Therapeutics Inc. Prior to joining Viron, Mr. Warma was co-founder and President of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies, which was ultimately sold to a large public European firm. Prior to MedExact, Mr. Warma held several senior management positions at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland in international policy and advocacy and in global marketing. Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International M.B.A. from the Schulich School of Management at York University in Toronto. He currently serves on the Board of Directors of BioHouston, Inc. Nicole Vitullo, Partner, Domain Associates ORGANISERS Nicole Vitullo joined Domain in 1999 and became a Partner in 2004. Present board memberships include Achillion Pharmaceuticals, Celator Pharmaceuticals, Durata Therapeutics, Esperion Therapeutics, Marinus Pharmaceuticals and VentiRx Pharmaceuticals. Past Board memberships include Calixa Therapeutics, Cerexa, Eunoe and Onyx Pharmaceuticals. In addition to investment responsibilities, she is involved in the distribution/liquidation strategies for the public companies in DomainвЂ™s venture capital portfolios. From 2000 to 2011, Ms. Vitullo was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies. From 1992-1999, Ms. Vitullo was Senior Vice President at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. From 1991-1992, Ms. Vitullo served as the Director of Corporate Communications and Investor Relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Ms. Vitullo spent 12 years at Eastman Kodak, most recently in Corporate Development where she was involved in the development and management of KodakвЂ™s venture capital activities. SUPPORTING ORGANISATIONS Neil Warma was appointed President and Chief Executive Officer of Opexa Therapeutics, Inc. in June 2008. He has more than 19 years of executive level experience in the life sciences industry in the U.S., Europe and Canada. Prior to joining Opexa, Mr. Warma served as President & CEO and a member of the Board of Directors of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company developing a novel class of protein therapeutics. While at Viron, Mr. Warma positioned the company as a leader in the treatment of serious inflammatory disorders. PRESENTING COMPANIES Michael Kotsanis has over 20 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. He is the Chief Commercial Officer for Synthon, a position he has held since mid 2010. Synthon is a fast growing specialty pharmaceutical company based in The Netherlands and is a leader in the field of generic medicines. Synthon employs over 1400 people in 11 countries. At Synthon he is responsible for developing and expanding its global business operations leveraging the companyвЂ™s world class product portfolio and R&D capabilities. Until mid 2010, he served as President, Europe, Middle East and Africa for Hospira, where he was responsible for developing strategy, delivering growth and attaining market leadership in the EMEA region. Kotsanis joined Hospira following its acquisition of Mayne Pharma in 2007, where he served as President, Asia-Pacific. From 2002 he had responsibility for leading MayneвЂ™s commercial and technical operations and associated activities across the Asia Pacific region. He joined Mayne following their acquisition of F H Faulding Pharmaceuticals in 2001, where he held responsibility for sales and marketing strategy and execution in Australia and New Zealand. Prior to Faulding, Kotsanis began his career with Boehringer Ingelheim where he held a variety of sales and marketing positions over an 11 year period. Kotsanis earned a bachelor of science degree from Monash University, Melbourne and a masterвЂ™s degree in business from the University of Technology, Sydney. SPEAKERS Michael Kotsanis, Chief Commerical Officer, Synthon BV t back :: next u Mette Kirstine Agger was a broad a broad international experience within biotech / life science covering business development and licensing, management and financing, including as CEO and co-founder of 7TM Pharma. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her carrier as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA. Mette Kirstine work as board member including position as board of director in Allocure, PsiOxus and Veloxis. WELCOME Speakers Ole Henrik Brekke, CEO, Vaccibody AS Ora Dar, Head of the Life Sciences Sector, Office of the Chief Scientist, Ministry of Industry, Trade and Labor, Israel Paola Casarosa, Global Head Business Development and Licensing Respiratory, Boehringer Ingelheim Paola Casarosa received a master degree in medicinal chemistry at the University of Torino, Italy, and a Ph.D. in molecular pharmacology, at Vrije Universiteit in Amsterdam. After a Post-Doc experience at Bichat Hospital in Paris, she joined Organon NV/ Schering Plough, as laboratory head in the therapeutic area of Reumathoid Arthritis. Since 2007 Paola has been working in Boehringer Ingelheim, where she covered different positions within Research and Development for respiratory indications and then within the Business Development & Licensing group, as global head of Licensing for Respiratory Diseases. Recently she took over additional responsibilities in the area of PM Strategy and Portfolio-management. SUPPORTING ORGANISATIONS Dr Ora Dar is the Head of the Life Sciences Sector at the Office of the Chief Scientist at the Israeli Ministry of Industry, Trade & Labor, and the Consultant for Biotechnology to the Chief Scientist. Being the head of the sector, Dr. Dar leads the team of experts recommending the granting of financial support by the Chief Scientist to projects in the field of Life Sciences. Dr. Dar is also responsible for defining and implementing tools and new programs required for supporting R&D in Life Sciences companies, and for enhancing the technology transfer between the Academia and the Industry. This has lead to the initiation and maturation of several viable programs such as, funding academic applied research, dedicated scheme for biotechnology incubator(s), tracks enabling collaboration with global Life Sciences companies, tools for upgrading infrastructures, and a special government backed Bio Funds. Previously she spent 16 years in academic research (mostly at the Weizmann Institute of Science), several years in the industry, and 10 years as a consultant to venture capital and investment firms as well as foreign funds and international R&D programs. Dr. Dar is a medical sciences graduate of the Hebrew University of Jerusalem and holds a Ph.D. from the University of London, UK (St. MaryвЂ™s Hospital Medical School, Imperial College of Science, Technology and Medicine). PRESENTING COMPANIES Olga Potapova is an expert in biotechnology, life sciences business development, biomedical technology transfer and international alliance management. Since 2003, she is a CEO and Scientific Director of Cureline, Inc., a human biospecimen CRO specializing in human tissue research projects including study design, regulatory affairs, clinical network management, specimen collection and analysis, and complete logistics. At Cureline Olga is responsible for strategic development, international alliance management, new products and services development, and expansion into new markets. Cureline is an international biomedical project management group of companies working in the areas of preclinical and translational research (www. Cureline.com), and diagnostic and laboratory services (www.CurelineBioPathology.com). Previously Dr. Potapova worked in the fields of cancer research (NIA, NIH); human molecular genetics and genomics; oncology drug R&D and translational medicine (SUGEN/Pfizer). Olga has received multiple AACR/AFLAC awards, NIH and NATO fellowships, and has published multiple scientific papers in peer-reviewed journals. She has advanced degrees in Physics (M.Sc.) and in Molecular Genetics/ Biochemistry (Ph.D.). SPEAKERS Olga Potapova, CEO and Scientific Director, Cureline Inc. t back :: next u Ole Henrik Brekke M.Sc , Ph.D 1994 from the Institute of Molecular Cell Biology, University of Oslo. Ole HenrikвЂ™s scientific work has fostered significant understanding to the function of human antibodies and he is author of more than 20 papers including Nature, PNAS and Nature Reviews in Drug Discovery, and is the inventor on several patents in recombinant antibody technology. He has been a senior scientist at UiO and National Institute of Public Health and has had R&D director positions in Affitech and Dynal-Invitrogen. He was in business development at Birkeland Innovation before joining Vaccibody in 2008. ORGANISERS WELCOME Speakers Pascal Touchon, Director вЂ“ Scientific Operation & BD, Les Laboratories Servier SPEAKERS t back :: next u Pascal Touchon has 26 yearsвЂ™ experience in the pharmaceutical industry in Research, Marketing and Sales, General Management and Business Development. He has extensive international experience in managing commercial operations and as CEO in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada, and South Africa. As head of Business Development for Servier over the last 3 years, he led the closing of more than 18 partnerships with biotech companies and academic institutes, managed various existing alliances and conducted two company acquisitions. Servier is a private research based pharmaceutical company with sales of 3.9 billion euros worldwide and activities in cardiovascular diseases, type II diabetes, neurology, psychiatry, rheumatology and oncology. Pascal holds a Doctorate in Veterinary Medicine, a DESS in Management and an MBA from INSEAD. Patrick Verheyen, Head, Johnson and Johnson Innovation вЂ“ London, Johnson and Johnson Patrick Verheyen is Head of the Johnson & Johnson Innovation Center in London вЂ“ a new organization dedicated to identifying, fostering and on-boarding early-stage science, technology and products to Johnson & Johnson businesses in the Pharmaceutical, Consumer and MD&D sectors. Patrick joined Johnson & Johnson in 1985 at Janssen Pharmaceutica N.V. in Beerse, Belgium. In 1996, he relocated to the USA as Director, Business Development, Pharmaceuticals Group, and in 1997, was promoted to Vice President, Corporate Development, Ortho-McNeil Pharmaceutical. He studied bio-engineering at the University of Leuven, Belgium. Peter plays an important role in supporting innovation in Northwestern Switzerland. His main focus is life sciences start-ups. Peter is CEO of вЂњEVA the Basel Life Sciences Start-up agencyвЂќ. This company was founded in 1996 with the aim to support life sciences start-ups with coaching, access to a high value network and providing seed money. In addition he is CEO of the BASEL INCUBATOR, which he helped to establish 2 years ago. The BASEL INCUBATOR is a joint venture of the University of Basel, the University of Applied Sciences of Northwestern Switzerland (FHNW) and the Canton of Basel-Stadt. To complement his activities, Peter is the president of the BioValley Business Angel Club, the only Business AngelвЂ™s Club in Switzerland focusing entirely on life sciences / MedTech. Peter has a PhD in chemistry from the University of Basel and joined Ciba-Geigy / Novartis 1984 as a research chemist. Throughout his professional career he had managerial positions with worldwide responsibility in technical development, regulatory affairs, manufacturing, production and communication and was the CEO of the subsidiary of a sector of Novartis in Germany. He joined EVA in 2006. SUPPORTING ORGANISATIONS Peter E. Burckhardt, CEO, EVA the Basel Life Sciences Start-up agency PRESENTING COMPANIES Patrick was most recently Vice President, New Ventures within Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, he led a nimble and diverse team that facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow. Prior to that, Patrick was Vice President, Mergers & Acquisitions within the Pharmaceuticals Group. In this role, Patrick facilitated strategic collaborations and acquisitions including Crucell, Elan and Cougar Biotechnology, and established a spin-out company, Movetis, based on Johnson & JohnsonвЂ™s gastrointestinal pipeline portfolio. Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large cap space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations (CROs), private equity and government institutions. Philippe Calais, CEO, Antisense Pharma GmbH ORGANISERS Dr Philippe Calais is Chief Executive Officer of Antisense Pharma since March 1, 2012. He has over 25 years of biopharmaceutical and pharmaceutical industry experience in both North America and Europe. Prior to joining Antisense Pharma, he was the President and CEO of Univalor, the largest technology transfer organization located in Montreal, Canada. He has managed biopharmaceutical companies in Canada and served as a consultant to life science companies, focusing on corporate strategic positioning, company deployment and sales optimization strategies. His management expertise, combined with extensive experience with large pharma companies such as ICI Pharmaceuticals and Roche, covers the full scope of the drug chain вЂ“ from discovery to clinical development, commercialization as well as partnership and franchise strategic marketing for several therapeutic areas. He has a degree and doctorate in pharmacy from the U. F. Rabelais, Tours, France. WELCOME Speakers Rahul Aras, CEO, Juventas Therapeutics, Inc. SPEAKERS t back :: next u Rahul Aras Ph.D. (President and Chief Executive Officer) is the founding CEO for Juventas. He is also a co-founder of SironRX Therapeutics, a company focused on novel regenerative therapies in the dermal and cosmetic fields. He has raised more than $35 million in venture capital and grant funding to transition both companies from concept into mid-stage clinical trials. Prior to Juventas, Rahul was the Director of Life Science Commercialization at Cleveland Clinic Innovations (CCI) where he is managed commercialization of all biotechnology and pharmaceutical related technologies. He has extensive experience negotiating licensing deals and strategic partnerships ranging from top 10 pharmaceutical companies to newly formed startups. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University. He has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. Rainer Henning, CEO, Biomay AG Regina Hodits, General Partner, Wellington Partners Regina Hodits joined Wellington Partners in spring of 2010 as General Partner for Wellington Life Science. With over 12 years of investing experience and a strong scientific background, she has become an influential investor in the European venture capital scene, focusing on early-stage and growth deals in Life Sciences. Prior to joining the Wellington team, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm. As a Partner at Atlas, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, F-star and Jenavalve. Furthermore, she served on the Board of Egalet, Novamed (public on NASDAQ via merger with SCLN) and U3 Pharma, which was acquired by Daiichi Sankyo Co.,Ltd. in 2008. From 2000 to 2004, while working for Apax Partners, she was closely involved with investments in Genmab, Silence Therapeutics and Wilex. She began to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000. In the 90s, Regina worked as a university lecturer and post-doctoral researcher at the University of Vienna, Austria and the MRC Cambridge, UK. Regina studied chemical engineering and holds a Ph.D. in biochemistry. SUPPORTING ORGANISATIONS Since joining Wellington, Regina has managed the investment in Oxagen, Oxford, UK; was instrumental in creating the PhilipsвЂ™ spin-out Sapiens, in Munich, Germany and Eindhoven, the Netherlands; and helped to establish Singapore founded AyoxxaвЂ™s presence in Cologne, Germany. In addition, Regina serves as an external Board member for the GSKвЂ™s respiratory therapy area unit (TAU). PRESENTING COMPANIES Rainer Henning serves as Chief Executive Officer of Biomay AG since January 2011. He looks back on a distinguished career of over 30 years in the biotechnology, pharmaceutical and venture capital industry. Before joining Biomay, he was Chief Executive Officer of Fibrex Medical, Inc., a biopharmaceutical company in the field of critical care medicine, a position he took over after working as investment manager and partner of two European venture capital funds for several years. His experience in the pharmaceutical industry encompasses operational and senior executive R&D positions in Hoechst AG, Hoechst Marion Roussel and Aventis. A chemist by training, he is inventor of over 80 granted patents, which cover among others the blockbuster antihypertensive ramipril. In addition, he has advised and served on the board of a number of biotechnology companies. Richard Goodfellow, CEO, Scancell Holdings Plc. Richard has over 30 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the companyвЂ™s flotation on the London Stock Exchange and successfully negotiated numerous deals. ORGANISERS In addition to co-founding ScancellвЂ™s ImmunoBody cancer vaccine business, Dr Goodfellow was also a co-founder of Paradigm Therapeutics, a Cambridge based functional genomics company and was a former Director of Enact Pharma plc. WELCOME Speakers Roberto De Ponti, Senior Director, Corporate Business Development, Helsinn Healthcare SA SPEAKERS During his career Dr. De Ponti was instrumental in the development of many oncology drugs, including new formulation of anthracyclins and sunitinib with Pharmacia/Pfizer, and a variety of other oncology projects working as consultant to several companies. Under his direction, on a yearly basis he was responsible for investigational supplies to more than 8000 patients worldwide, and for market production of 50 Million units of oncological drug units per year. Since 2008 he is Head of Corporate Business Development with Helsinn, a privately owned pharmaceutical group with headquarters in Lugano (Switzerland), and operating units in Biasca (Switzerland), Ireland, United States, and a representative office in Beijing, China. t back :: next u Roberto De Ponti a Pharmacist by training and an EU Qualified Person, started his career in pharmaceutical analysis in the former Farmitalia Carlo Erba, followed by formulation and drug development. His responsibilities grew while the company went an impressive series of M&As (from Farmitalia Carlo Erba to Kabi Pharmacia, Pharmacia & Upjohn, Pharmacia with the merge with Searle, and eventually Pfizer), getting site responsibilities for drug substance and drug product development and manufacturing of investigational and marketed products. He was also site lead of the R&D Italian site of Pharmacia (specialized in Oncology) and eventually followed the transition to Pfizer and also the transition to an independent spin-out company (Nerviano Medical Sciences), where he became responsible for the Pharmaceutical Science section bringing it to break even offering development services to oncology companies wordwide. HelsinnвЂ™s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. In the last four years he was instrumental to the acquisition of two oncology related development programs for Helsinn, and other advanced negotiations are expected to be positively concluded during the current year. In addition, a portfolio of products filling the integrative medicine needs in oncology has been implemented. Ron Laufer, Senior Managing Director, Medimmune Ventures PRESENTING COMPANIES Dr. De PontiвЂ™s current responsibilities include external research of R&D projects mainly in the areas of Cancer Supportive Care and Cancer Therapeutics focusing on Phase II completed programs, and execute the due diligence and negotiation activities for in-licensing products. Dr Ron Laufer is the head and Senior Managing Director of MedImmune Ventures, a $400M evergreen venture capital fund. The fund, which is a subsidiary of the AstraZeneca Group, invests in BiopParmaceutical, MedTech and Healthcare IT start-up companies in North America, Europe, Israel and Australia. Ron received his B.Sci., M.D. and M.P.H. from Hebrew University, and an M.B.A. from the Harvard Business School. He is currently an adjunct Professor of business administration at the Kelley Business School of Indiana University Ron Nager, President & CEO, Insuline-Medical Ltd SUPPORTING ORGANISATIONS An experienced healthcare investor, Ron started his career as a physician before moving into venture capital. He was a co-founder of Lilly Ventures, the venture capital arm of Eli Lilly & Company, and later a Managing Director at Visium Asset Management, a private healthcare-focused investment firm, before joining MedImmune Ventures in 2010. ORGANISERS WELCOME Speakers Rudi Neirinckx, CEO, Ennar Pharma AG Rudi D Neirinckx is an experienced pharmaceutical industry executive and author of over 100 scientific publications and more than a dozen patents. He worked in most aspects of the pharmaceutical business, i.e. research, clinical development, licensing, business development, etc. in the diagnostic as well as the therapeutic side of the business. He also was a consultant for the NASAвЂ™s Space Shuttle program. SPEAKERS t back :: next u After an academic career in Nuclear Medicine and radiology, producing radioisotopes with a cyclotron and developing novel radiodiagnostic products, he headed up the R&D operations of Amersham International (UK) and Serono (Geneva). He was responsible for reorganizing the M&A Department of Merck KGaA, where he made numerous license and M&A deals, including a major license deal with Imclone Systems. He founded an OTC Company (Agys Pharma, Belgium), based on his invention of an effective treatment of dental sensitivity and was COO of a Generics Company (PAR Pharmaceuticals, USA), which he helped turn around. He also was CEO of atugen, a Berlin high-tech start-up, before he became a full-time consultant in Oncology to the President of Altana Pharma. Subsequently he has exclusively worked on the psoriasis project, which is now property of and developed by Ennar Pharma AG. Rustam Ixanov, Vice-President of Strategic Development, AKRIKHIN OJSC Rustam Ixanov was born in 1973 in Nizhniy Novgorod, Russia. In 1996 graduated from State Medical Academy. From 2000 till 2002 he was a Head of Medical department of В«NizhpharmВ», STADA Group. Later he was R&D Director (В«NizhpharmВ», STADA Group, 2002-2006). Before В«AKRIKHINВ» Rustam was a Development Portfolio Director of pharmaceutical company вЂќIzvarino PharmaвЂќ (Ferring Pharmaceuticals is the most significant investor of this company). From September 2010 he has been the Vice-president of strategic development at вЂњAKRIKHINвЂќ OJSC with responsibilities for: Strategic Portfolio Development, Product Development, Business Development, Intellectual Property, Regulatory Affairs, Preclinical/Clinical trials, Pharmacovigilance. PRESENTING COMPANIES Rustam began his career in pharmaceutical business as a manager of medical information in pharmaceutical company В«NizhpharmВ», STADA Group(1999-2000). Saira Ramasastry, Managing Partner, Life Sciences Advisory LLC Saira is a recognized thought leader on public-private alliances and is frequently called upon as a speaker. She serves on the Industry Advisory Board of the Michael J Fox Foundation for ParkinsonвЂ™s Research, the Board of the American Liver Foundation and as a Special Advisor to the California Institute for Regenerative Medicine. Saira has a B.A. in Economics with Honors and Distinction from Stanford University where she graduated Phi Beta Kappa, and advanced degrees in Management Science & Engineering and Management Studies from Stanford University and the University of Cambridge. She currently serves on the Advisory Council for the Cambridge Judge Business School and was recently named to the Silicon Valley/San Jose Business JournalвЂ™s 40 under 40 list. SUPPORTING ORGANISATIONS Saira Ramasastry, Managing Partner of Life Sciences Advisory, is a seasoned industry insider with approximately 15 years experience and who has advised on over 80 transactions. Prior to LSA, Saira led emerging biotech coverage at Merrill Lynch for over a decade where she helped establish the leading life sciences franchise on Wall Street. Prior to Merrill Lynch, Saira worked in M&A and Restructuring at Wasserstein Perella. ORGANISERS WELCOME Speakers Sarah Holland, Global Head, Strategic Partnering, Roche Partnering SPEAKERS Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast cancer during US and EU launch. She held various commercial and strategic roles over her ten years there, including Global Strategic Planning Manager for early compounds, Pricing Strategist and Health Economist. Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies. t back :: next u Sarah Holland is the Global head, Strategic Partnering for Roche Partnering based in Basel, Switzerland. Her teamвЂ™s projects include broad strategic landscapes of M&A and late stage opportunities, transactional support for all pharma M&A transactions, initiatives to generate income through divestments, spin-outs and strategic partnerships, and development and delivery of creative deal structures to address key business needs. In 2010 the team acquired world-wide rights to danoprevir from Intermune and supported the acquisition of Marcadia Biotech. Since joining Roche in 2005, Sarah has held various responsibilities in business development, such as Global Head of CNS Partnering, and has led projects in a range of disease areas, including the Plexxikon deal on b-raf inhibitors. Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D.Phil and first degree at Oxford University. SГёren Moller, Managing Investment Director, Novo A/S Prior to joining Novo Seeds, SГёren served as global manager of Bioinformatics and Genomics at Novozymes. Before Novozymes, SГёren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA based products for life science research, pharma services and diagnostics. In 2007 Exiqon completed an IPO on NASDAQ OMX Copenhagen raising 400 mio DKK to develop and commercialize life science and diagnostic products. Previously, SГёren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk. Since 2008, SГёren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark). SГёren serves on the board of directors of Denator AB, a Swedish based biotech company. PRESENTING COMPANIES SГёren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark for a project on molecular microbiology. In addition to his PhD, SГёren has academic training as postdoctoral fellow at Stanford University School of Medicine. Stan Yakatan, Chaiman & Co-Founder, Katan Associates New England Nuclear вЂў EI Dupont вЂў ICN Pharma вЂў New Brunswick Scientific вЂў Biosearch These experiences have provided him with management skills and a corporate finance acumen that he enjoys sharing with others. Stan has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany. In many cases he has also served as the initial CEO, and Chairman of these companies. In his career, he has advised several of the worldвЂ™s leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA), and Biocapital (Canada). During the decade of the 1990вЂ™s Biocapital was the most successful venture capital fund in Canada. Stan currently serves in a business development capacity for the XL TechGroup (AIM: XLT). The XL Tech Group systematically discovers unmet business needs, then creates, selects, and develops new technology businesses, and scales them to liquidity. Stan assisted XL TechGroup in the development of its business model, and advised on the overall capitalization strategy for XL Tech Group. In October 2004, XL TechGroup undertook an Initial Public Offering in connection with its listing on the Alternative Investment Market (вЂњAIMвЂќ), raising in excess of $40.0 million. Stan is currently the Chairman of Grant Life Sciences, Inc., (OTCBB:GLIF) a company developing a revolutionary test for the screening of cervical cancer. Stan is also a member of the Board of Directors of Biophan, Inc. (OTC.BB). Stan serves as the strategic advisor to the State Government of Victoria, Australia. Stan is also the Executive Director and Chairman of Biocomm, in Melbourne, Australia, the first of its kind regional business development agency and early-stage capital pool. Stan currently sits on the Board of Mercury Therapeutics, Inc. which is developing new drugs for diabetes and obesity, and Phenomenome Discoveries, Inc., a novel biomarker company. ORGANISERS Stan has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0 billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, вЂњCapital Raising for the Technology-Based Start-UpвЂќ and вЂњThe Need to be Global in the Quest for Capital and PartnersвЂќ. Rick Biondi, Editor of Lab Business Magazine stated,вЂќ Mr. Yakatan is a venture capital raising Guru and it is part of his genetic make up.вЂќ SUPPORTING ORGANISATIONS After 30 years as a successful CEO, entrepreneur, and operational manager, Stan Yakatan has dedicated the last 12 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as a вЂњCвЂќ level executive is far reaching he has served in such a capacity with: WELCOME Speakers Stephanie LГ©ouzon, Senior Advisor, Torreya Partners Stephanie is a Senior Advisor at Torreya Partners, a life sciences advisory boutique. She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology, pharmaceutical and speciality pharmaceutical sectors. SPEAKERS Prior to joining Credit Suisse in 1998, StephanieвЂ™s experience included working in Health Care at Lehman Brothers, JP Morgan and Salomon Brothers (now Citigroup). Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985. t back :: next u She has advised clients on a number of strategic transactions, valued at over $70 billion, and she has been involved in financing transactions to provide over $7 billion to healthcare clients. Thomas KГјndig, CoChair, Colby Pharmaceutical SAB Dr. KГјndig pioneered studies on the biology of cytotoxic T lymphocytes together with Dr. Rolf Zinkernagel. Dr. KГјndig completed medical school at the University of Zurich in 1987 and went on to earn a medial thesis in respiratory physiology, also at the University of Zurich. Enrolled in the postgraduate course for experimental medicine and biology, he studied immunology as a post-doctoral fellow in the laboratory of Nobel laureate Professor Zinkernagel, where his work began on understanding how immune responses are stimulated and maintained. Dr. KГјndig has published numerous scientific papers in leading journals such as Nature, Science, Cell and Immunity with cumulative citations >11вЂ™000 and an h-index of 47. He has received several fellowships from the Swiss National Research Foundation and the Cancer League. Since 1998 Dr. KГјndig lectures in dermatology, allergology and immunology at the University of Zurich. He was given the Georg Friedrich GГ¶tz Award for outstanding medical research in 1999, and was nominated in 2000 by the Ludwig Institute for Cancer Research as an affiliate researcher. PRESENTING COMPANIES From 1992-95 KГјndig trained in molecular biology and immunology with Dr. Pamela Ohashi and Dr. Tak Mak in the Department of Medical Biophysics at the Princess Margret Hospital in Toronto. Since 1995 he has worked as a clinical dermatologist and allergologist/clinical immunologist at the University Hospital in Zurich, where his research group specializes in allergen and cancer immunotherapy. Dr. KГјndig spends 50% of his time in the clinics, where he supervises and is responsible for the outpatient dermatology clinics, including general dermatology, radiotherapy unit, UV therapy unit, Laser unit, oncology unit, unit for autoimmune diseases, hair clinics, epicutaneous testing unit, allergy unit, the center for inflammatory skin diseases, the dermatology emergency unit, and the unit for sexually transmitted diseases. SUPPORTING ORGANISATIONS Dr. KГјndig currently is the head of research and the routine laboratories of the Dermatology Department. Overall the laboratory and research department has a size of approx. 50 employees, with approx. one third technical staff and two third academics. Dr. KГјndigвЂ™s own research group currently consists of 2 PhD post docs, 2 PhD students, and 3 MDs and focuses on translational research. His research group develops products and strategies taking them from basic immunology to preclinical animal models and finally into the clinics. As translation into the clinics requires extensive regulatory work, toxicology studies and funding for GMP production, the research group closely collaborates with the industry. When developing products for which no industrial partners can be found, Dr. KГјndig was and still is also involved in founding spin-off companies as vehicles to fund further clinical development. Dr. KГјndigвЂ™s research group is certified by the Swiss Medical Society as a teaching site for pharmaceutical development. In very close collaboration with the center for clinical trials he is currently performing numerous phase I and II studies in immunotherapy, allergy and dermatology. Thomas van Elzakker, COO, i-Optics ORGANISERS Thomas van Elzakker joined i-Optics in July 2012 as COO with responsibilities for R&D, product management and global supply chain operations. His move to i-Optics followed 16 years with Philips Healthcare, where he held positions in marketing and general management in various business units and field organizations. From November 2000 to December 2005, Thomas lived and worked in the USA and was the global marketing and strategy executive for the Philips CT scanner business in Radiology. More recently, he was General Manager for New Ventures in the Global Services organization of Philips Healthcare, building a successful new professional services venture. Thomas holds an MSc in Applied Computer Science from Leiden University in the Netherlands.. WELCOME Speakers Thomas Taapken, CFO, Epigenomics AG SPEAKERS t back :: next u Dr Thomas Taapken is acting as sole member of the Executive Board of the Epigenomics AG since September 30, 2012. He joined Epigenomics on April 1, 2011 as Chief Financial Officer from Biotie Therapies (Finland), where he held the position of CFO and was a member of the Executive Management Team. He was appointed to this position in 2008, following a business combination between Biotie Therapies and elbion NV, where Thomas had been CFO since 2005. His extensive international experience in the life sciences industry includes previous positions as Investment Partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Francisco-based US venture capital firm Burrill & Company from 1998 вЂ“ 2002. He also worked several years at Sanofi-Aventis in the U.S.A. and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings. Timothy Herpin, VP SPBD Oncology & STL, AstraZeneca Timo Veromma, President & CEO, Biotie Therapies Corp. Timo Veromma, President and CEO from May 2005, Vice President, R&D 1998-2005; Medical Director, Schering AG (Finland; 1996-1998); Program Director at Collagen Corporation (California, USA, 1994-1996); Postdoc Fellow at Stanford University (California, USA, 1990-1993). PRESENTING COMPANIES Timothy Herpin joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS & Pain and more recently for Oncology & STL. In this role, he leads a team of business development professionals involved in all aspects of deal making for the Oncology franchise. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction execution in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern. Finnish Bioindustries, Chairman of the Board. Chairman of the Steering Committee for HealthBIO, a national cluster program focusing on health applications of biotechnology. Chemical Industry Federation of Finland, Member of the Board of Directors. Hermo Pharma Ltd, Member of the Board of Directors. Thomas Stockman is a Director in the Global Healthcare Group. He joined Citi in 2002 and has more than 10 years of investment banking experience. He has worked with many companies in the biopharma and healthcare services sectors, including advising GSK on its increase in ownership of GSK Consumer Nigeria, Nabriva on its option agreement pursuant to sale with Forest Laboratories, Roche on its acquisition of Anadys, Hikma on its acquisition of Promopharm, Solvay on the sale of its pharmaceutical business to Abbott, Huvepharma on the sale of a 38% stake to CVCI, Montagu on its acquisition of a stake in Euromedic, BUPA on the sale of its hospitals to Cinven, Numico on its sale to Danone, Savient Pharmaceuticals on the sale of Rosemont to Close Brothers Private Equity, KPC on the sale of its stake in Aventis to Sanofi-Synthelabo, Sante Luxembourg (Cinven, Vivendi and ABN) on the disposal of its stake in General de Sante to Sante Holdings; Roche, AstraZeneca, Bayer and Merck KGaAвЂ™s bonds; financing EQT and InvestorвЂ™s LBO of Gambro, HikmaвЂ™s UK IPO and subsequent AEO. He also worked on the Halfords IPO in the retail sector. SUPPORTING ORGANISATIONS Thomas Stockman, Director Healthcare Investment Banking, Citi Group. Thomas has a degree in Biological Sciences from Oxford University. ORGANISERS WELCOME Speakers Tomer Kariv, Co-Founder & CEO,, Pontifax Corp. Tomer Kariv is the co-founder and Chief Executive Officer of Pontifax, a group of Israeli based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies. Mr. Kariv serves as an active board member of many of the fundsвЂ™ portfolio companies, assuming a special responsibility for strategic planning. SPEAKERS t back :: next u Among others, Mr. Kariv serves as the Chairman of Check-Cap Ltd and is a board member of Macrocure Ltd, Arno Therapeutics Inc. and Aposense Ltd. During the 10 years prior to establishing Pontifax, Mr. Kariv played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv practiced law with Sullivan & Cromwell, a leading corporate law firm in New York, and holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School. Vasily Ignatiev, CEO,, R-Pharm VincenГ§ Tur, CEO, Lipopharma Vincent Charlon, CEO, Anergis Vincent Charlon joined Anergis in January 2009 as Chief Executive Officer (CEO), bringing over 20 years of global clinical development and management experience. From 1990 to 1998, at Hoffmann La Roche in Basel and then in Nutley, USA, Vincent Charlon held clinical development responsibilities for several international projects. From 1998 to 2006, Vincent Charlon was CEO of Hesperion Ltd., the contract research organization (CRO) who designed and conducted all initial clinical trials for ActelionвЂ™s [SWX, ATLN] products. In this capacity, Vincent Charlon designed the first clinical trials of TracleerВ® in pulmonary hypertension, today ActelionвЂ™s biggest product with sales well over CHF 1 billion/year. Vincent Charlon developed Hesperion into a profitable CRO from 3 to 200 employees serving over a hundred clients, mostly European and North American biotechs. In 2007-2008, Vincent Charlon was CEO of the drug repositioning start-up company LS Pharma International SA before joining Anergis where he led the round A financing of CHF 18 M early 2011. SUPPORTING ORGANISATIONS Economist by training, his previous professional career has been in a financial institution (Bank of Ibiza) and at the Confederation of Industries in the Balearic Islands (CAEB), as chief economist. During his 20 years at CAEB he has been a reputed regional economist and has gained significant experience in managing research projects and promoting initiatives to drive innovation into leading regional companies with strong international implantation. He has also been directly involved in the start-up of several Technology-based companies. As co-funder of Lipopharma, since 2006 he has significantly contributed to the consolidation of an academic spin-off into a sound global biopharmaceutical company. As LipopharmaвЂ™s CEO he has negotiated and signed several licensing deals, including 3 in-licensing agreements with the University of the Balearic Islands (three patents related to oncology indications of Minerval and other modified lipids), one in-licensing deal with the Paraplejic General Hospital in Toledo (for Spinal Cord injury and Pain program) and one out-licensing deal with AB-Therapeutics (now Ability Pharmaceuticals) for cancer indications of a family of synthetic lipids protected by a patent filed by Lipopharma in October 2009. PRESENTING COMPANIES Since 2008 works at R-Pharm as Director for Business Development, then CEO. 5 years at the Russian headquarters of the international pharmaceutical company AstraZeneca in the positions of Marketing Director, Sales and Marketing Director, National Sales Director. 7 years at the Russian headquarters of the international pharmaceutical company Bristol-Myers Squibb in the positions of Product Manager, Franchise Manager, Marketing Director. In 1998-1999 spent 7 months on secondment at the global marketing group of BMS corporate headquarters in Princeton, NJ. MD вЂ“ diploma with honors, Moscow Sechenov Medical Academy (incl. 6 months elective courses at Columbia University College of Physicians and Surgeons (Ney York, NY)). Major in clinical pharmacology. PhD вЂ“ Moscow Sechenov Medical Academy & Russian Academy of Medical Sciences. MBA вЂ“ Moscow MIRBIS business school & London Guildhall University. ORGANISERS WELCOME Speakers Vladimir Kovalskiy, Co-Founder & CEO, TN LLC Vladimir is a Computer Science graduate born in the family of doctors. Medical environment he was grown in influenced his vision and passion for the healthy lifestyle. He started company together with his partner Dmitry Lazutkin back in 2008. In course of 5 years Medesk solution was developed with the idea to integrate all players of the healthcare market and provide the better care for patients. . SPEAKERS Vladimir has relative experience working in Japan. Speaks Russian, English and Japanese. t back :: next u He is an avid supported of digital healthcare adoption. Looking for the technology to help more people in getting access to medical treatment and diagnostics. PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS WELCOME Ability Pharmaceuticals www.abilitypharma.com CONTACT Carles DomГЁnech, PhD Chief Executive Officer TELEPHONE + 34 93 586 8977 EMAIL contact@abilitypharma.com The company is developing a patented new drugs class called Lipid Analogue Therapeutics, which is highly differentiated and has an innovative mechanism of action. Abilitpy Pharmaceuticals currently has two candidates in development: ABTL0812, which is finishing preclinical development and is expected to move into phase Ib, First in Man clinical trials for lung and pancreatic cancer in the second quarter of 2013, and ABTL1014, which is expected to start preclinical development in spring 2013. ABTL0812 is an antiproliferative and cytotoxic drug with a novel mechanism of action (MoA). It was selected for preclinical development because, a) its activity over a wide panel of tumor cell lines (lung, pancreatic, lymphatic, liver, melanoma and glioma); b) its good efficacy in animal models of cancer; c) its low in vivo toxicity; and d) once dayly oral administration. Importantly, it shows synergistic properties with standard of care (SOC) drugs such as docetaxel and gemcitabine. ABTL0812 affects two major cell processes related with cellular division, and thereby with proliferation of tumor cells: a) inhibition of akt phosphorylation and mTORC1 and mTORC2 pathways, and b) DNA synthesis through the inhibition of dihydrofolate reductase (DHFR) gene expression. The modulation of these main cellular functions induces cell death by autophagy, a mechanism of self-digestion of the cell. PhD in Cell Biology & Business Training. 13 yrs in BDL at Almirall & Lacer. 2.5 yrs in biotech venture capital (Barcelona EmprГЁn and CIDEM). 8 yrs in science research, incl.2 yrs at Memorial Sloan-Kettering Cancer Center (New York). BS/MS Biology. JosГ© AlfГіn, PhD, VP Research & Development 4 yrs. Team leader drug development (pre-clinical and clinical) at the biotech Palau Pharma, SA. 8 yrs, team leader drug discovery at the pharmaceutical company Uriach, SA. PhD in Pharmacology , Research at Hebrew Univ. of Jerusalem and Universitat de Barcelona. BS/MS Pharmacology. t back :: next u MANAGEMENT Carles DomГЁnech, PhD, Chief Executive Officer - Co-founder. PRESENTING COMPANIES YEAR FOUNDED 2009 Ability Pharmaceuticals, SL is a biopharmaceutical company founded on November 28, 2009. The company is based in Bellaterra (Barcelona), on the Autonomous University of Barcelona campus. SPEAKERS ADDRESS Edifici Eureka вЂ“ Campus de la UAB 08193 Bellaterra (Barcelona Catalonia Spain COMPANY PROFILE Vanessa Ruz, Director, Finance & Administration Prior to Ability pharma years she was the Chief Financial Officer of Sevibe Cells, SL. BEc/MEc in Economics. SUPPORTING ORGANISATIONS ORGANISERS WELCOME Abliance (B Cell Design) b-cell-design.com CONTACT Dr Jean Sainte-Laudy Chief Executive Officer FINANCIAL SUMMARY 2011 Balance 320kв‚¬ COMPANY PROFILE B Cell Design is specialized in the conception and production of chimeric antibodies for clinical diagnosis and immunotherapy on the basis of patented KI mouse models producing IgG1, IgA1, IgM and IgE. B Cell Design having the capacity of producing human secretory piece, secretory IgA1 is also available. TELEPHONE +(33) 555 123 021 Pre-clinical phase has started in vitro and in vivo in mice for dimeric and secretory IgA1 anti-human CEA and specific and neutralizing IgA1 and IgG1 are available for different influenza strains in order to set up vaccination protocols. FAX +(33) 970 611 557 B Cell Design is also involved in other protocols as HIV and bacterial mucosal infections. SPEAKERS ADDRESS 98, rue Legendre, 87000 Limoges, France The main application of the secretory IgA1 is the direct mucosal treatment including the oral route due to itвЂ™s exceptional resistance to local proteases. Specific IgEs will have a major place in allegro-oncology. MANAGEMENT EMAIL jslaudy@b-cell-design.com PRESENTING COMPANIES t back :: next u YEAR FOUNDED 2007 Dr J Sainte-Laudy, immuno-allergist, CEO Dr Armelle Cuvillier, specialized in molecular biology, CSO Dr GaГ«l Champier, specialized molecular biology applied to microbiology, CTO SUPPORTING ORGANISATIONS ORGANISERS WELCOME AKRIKHIN OJSC www.akrikhin.ru CONTACT Business development department contact details E-mail: bd@akrikhin.ru Tel.: +7 (495) 702-95-13 Sales 2012: в‰€6 bln rubles (в‰€150 mln EURO) COMPANY PROFILE Part of Polpharma group, 150+ products (OTC, generics, original products) in several key therapeutic areas, R&D capabilities, manufacturing of solid, semisolid and liquid forms, Sales Force, sales in Russia and CIS. SPEAKERS ADDRESS AKRIKHIN Moscow Office Riverside Towers Business Center 115054, Russia, Moscow, Kosmodamianskaya Naberezhnaya, 52 bld 5, вЂњAKRIKHINвЂќ FINANCIAL SUMMARY TELEPHONE +7 (495) 721 36 97 YEAR FOUNDED 1936 t back :: next u EMAIL + 7(495) 723 72 82 PRESENTING COMPANIES FAX + 7(495) 723 72 82 SUPPORTING ORGANISATIONS ORGANISERS WELCOME Amakem N.V. www.amakem.com CONTACT Kieran Rooney, PhD Chief Business Officer FINANCIAL SUMMARY ADDRESS Amakem N.V. BioVille Agoralaan bldg. A bis 3590 Diepenbeek Belgium COMPANY PROFILE FAX +32 (0) 11 490-209 MANAGEMENT Jack Elands, PhD, CEO Dirk Leysen, CSO Steve Pakola, MD, CMO Olivier Defert, PhD, Director, Preclinical Product Development Maarten van Geffen, Head of CMC and Operations Kieran Rooney, PhD, CBO t back :: next u YEAR FOUNDED 2010 Amakem is an ophthalmology company developing new treatments for serious eye conditions. AmakemвЂ™s product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects. AmakemвЂ™s lead candidate, AMA0076, is for glaucoma and the Company is working to apply the Localized Drug Action approach to a range of other eye diseases. AMA0076 is currently undergoing Phase 2a proof of concept trials. The Company has a second ophthalmology asset in preclinical development in an undisclosed indication. Beyond ophthalmology, Amakem has preclinical development programs in asthma/COPD and inflammatory bowel disease. PRESENTING COMPANIES EMAIL info@amakem.com в‚¬18M Series A round (Aug 2011) SPEAKERS TELEPHONE + 32 (0) 11 286-982 в‚¬1.5M Seed round (Jan 2010) SUPPORTING ORGANISATIONS ORGANISERS WELCOME Anergis www.anergis.ch CONTACTS Vincent Charlon PhD, CEO FINANCIAL SUMMARY Zoltan Czigler MBA, Finance Director COMPANY PROFILE TELEPHONE +41 21 651 9220 FAX +41 21 651 9221 Anergis COPs reproduce the full-length amino acid sequence of the allergen in separate long peptides. COPs do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be safely administered at high doses to induce tolerance to the allergen after few injections only. Studies of COPs in vitro, in animals and in humans have confirmed the safety (no immediate allergic reaction) and immunogenicity (production of specific IgG4 antibodies and cytokines against the original allergen) of ANERGIS COPs. In a Phase I/IIA trial with AllerT, a trend for symptom improvement was observed during the season and long term follow-ups of the same patients demonstrated that antibodies against the birch pollen major allergen bet v 1 were still significantly elevated in comparison with placebo-treated patients, two and four seasons after the very short one-time preseasonal treatment (5 SC injections in 2 months) with AllerT. A large double-blind, placebo-controlled, randomized, multicentre European trial is underway with AllerT to demonstrate the efficacy of AllerT using recommended regulatory endpoints of combined symptom and medication scores in real-life conditions, i.e. during the natural birch pollen season. Results of this trial are expected in Q3 2013. At this time, Anergis intends to partner AllerT for Phase III and/or to finance it through a round B with current and new investors. PRESENTING COMPANIES YEAR FOUNDED 2001 AnergisвЂ™ lead-product AllerT, a vaccine to treat birch pollen allergy, is in Phase II clinical development. AllerR, its vaccine candidate for the treatment of patients with allergy to ragweed pollen has received positive feedback from the U.S. FDA for the final preclinical and early clinical program and AllerDM, AnergisвЂ™ vaccine candidate for patients with house dust mite allergy, is progressing through preclinical development. Anergis has raised over CHF 22 million from Renaissance PME-Vinci Capital, Sunstone Capital, BioMedInvest and other investors including Esperante Ventures and Defi Gestion. t back :: next u EMAIL info@anergis.ch Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel allergy vaccines targeting the most frequent allergies. AnergisВґ vaccines are based on its proprietary Continuous Overlapping Peptides (вЂњCOPвЂќ) technology. Allergies are the most prevalent and the fastest growing chronic conditions in the industrialized world, with over 500 million people affected. SPEAKERS ADDRESS BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland CHF 22M funding received from venture capital and private investors MANAGEMENT SUPPORTING ORGANISATIONS Vincent Charlon, PhD, CEO Christophe Reymond, PhD, CSO FranГ§ois Spertini, MD, Allergy Expert, Founder Gilles Della Corte, MD, Clinical Development Eva Castagnetti, PhD, Product Development Gerard Farmer, PhD, Regulatory Affairs Jean Paul Rohmer, PhD, Business Development Zoltan Czigler, MBA, Finance ORGANISERS WELCOME Antisense Pharma GmbH www.antisense-pharma.com CONTACTS Dr Philippe Calais CEO FINANCIAL SUMMARY Dr Andrea Kottke Head Medical Affairs & Communication Others are S-Refit and Bayern Kapital. Or: Leopoldstrasse 244 80807 Munich Germany COMPANY PROFILE Antisense Pharma is a biotech company based in Regensburg and Munich, Germany, developing innovative therapies targeting the TGF-Гџ pathway to treat tumor diseases with high unmet medical need. The companyвЂ™s lead compound, the antiВ¬sense oligonucleotide trabedersen, has been granted orphan designation for three tumor indications. Trabedersen has been found to be safe in several clinical trials and has shown encouraging clinical activity in patients suffering from high grade glioma, pancreatic cancer, or malignant melanoma. The target of trabedersen, TGF-Гџ2, is a key component of the TGF-Гџ signaling complex, and a key promoter of cancer-derived immunoВ¬suppression. Trabedersen, by down-regulating its expression, is believed to reverse the immunoВ¬suppressive effects, rendering the tumor visible to the patientвЂ™s immune system and resulting in priming and specific activation of the patientвЂ™s anti-tumor immune response. Antisense Pharma intends to further validate this promising drug candidate in selected indications. In addition, the company is expanding its pipeline through the development of a вЂњNext GenerationвЂќ oligo-nucleotide program identifying novel proprietary compounds to target cancer. EMAIL c.elsinger@antisense-pharma.com Dr. Philippe Calais, Chief Executive Officer t back :: next u MANAGEMENT FAX +49-941-9201329 PRESENTING COMPANIES TELEPHONE +49-941-920130 Equity lead investor is MIG fund. SPEAKERS ADDRESS Josef-Engert-Str. 9 93053 Regensburg Germany Privately held company. YEAR FOUNDED 1998 SUPPORTING ORGANISATIONS ORGANISERS WELCOME APIM Therapeutics AS www.apimtherapeutics.com CONTACT Kostas Alevizopoulos PhD Chief Executive Officer TELEPHONE +41 78 752 7002 COMPANY PROFILE APIM Therapeutics AS is a Norwegian biotech company set to develop and commercialize novel anti-cancer therapies potentiating chemotherapy-induced responses in cancer cells. We offer a unique physiological intervention point targeting a cellular вЂњhubвЂќ protein called Proliferating cell Nuclear Antigen (PCNA). PCNA acts a master regulator of replication, repair, cell cycle control and apoptosis, ultimately controlling responses to pathological (cancer) and pharmacological (chemotherapy) stress in cells. ATX-101, the companyвЂ™s current preclinical lead, features a novel PCNA-interacting Stress Switch Peptide Motif termed APIM. This motif, being incorporated in peptide sequence, interferes with several cellular defense systems dealing with stress resulting in both hypersensitivity to chemotherapy and direct induction of apoptosis in selected cancer cells. Overall, ATX-101 has shown potent preclinical efficacy including single agent activity and potentiation of the action of >15 clinical drugs in vitro (cisplatin, melphalan, bleomycin, cytarabine, decitabine, dasatinib, vorinostat, bortezomib and others) as well as proof-of-efficacy in animal models of blood cancer and solid tumor indications. Currently, ATX-101 is being developed as a novel candidate drug for various oncology indications. MANAGEMENT Kostas Alevizopoulos Ph.D., Chief Executive Officer Marit Otterlei Ph.D., Chief Scientific Officer t back :: next u YEAR FOUNDED Founded in 2009 as a spin out from the Norwegian University of Science and Technology in Trondheim (NTNU), Norway. Current investors include: вЂў Sarsia Seed вЂў Birk Venture вЂў Ro Invest вЂў Norsk Innovasjonskapital AS PRESENTING COMPANIES EMAIL contact@apimtherapeutics.com kalevizo@apimtherapeutics.com Venture Capital Financed. SPEAKERS ADDRESS APIM Therapeutics AS c/o NTNU Tech Transfer AS Sem SГ¦landsvei 14 Kjemiblokk 1, 3etg N-7491 Trondheim Norway FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME Apogenix GmbH www.apogenix.com CONTACT Dr Thomas HГ¶ger, CEFA CEO/CFO FINANCIAL SUMMARY ADDRESS Im Neuenheimer Feld 584 69120 Heidelberg Germany COMPANY PROFILE FAX +49 6221 5860810 EMAIL contact@apogenix.com Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for cancer treatment. The companyвЂ™s therapeutic candidates target either pathways inducing apoptosis or a pathway stimulating tumor cell growth and migration. The lead product candidate, Apoceptв„ў (APG101), is a CD95-Fc fusion protein that blocks the interaction between CD95 and its ligand CD95L, thereby inhibiting in cancer cells their proliferation and migration. Apogenix announced in 2012 that Apocept has reached all clinical endpoints in an actively controlled Phase II proof-of-concept study in patients with recurrent glioblastoma multiforme (GBM). The primary endpoint was progression free survival (PFS) at six months. Achieved secondary endpoints include PFS, overall survival (OS), safety and tolerability. The outstanding efficacy was combined with an excellent safety profile; no drug-related serious adverse events have been observed in all clinical studies conducted so far with Apocept. It is the first compound in more than a decade to clearly deliver a PFS as well as an OS benefit in an actively controlled trial. The inhibition of CD95L by Apocept holds great promise in other tumor indications such as myelodysplastic syndromes (MDS) and pancreatic cancer. To explore ApoceptВґs potential in MDS, a phase I study in MDS patients has been initiated in January 2013. Additonal studies in GBM are in preparation. MANAGEMENT Dr. Thomas HГ¶ger, CEO/CFO He joined Apogenix GmbH as CEO and CFO in November 2005. Prior to this, he worked as a stock analyst for DZ BANK, Frankfurt. From 1997 to 2000, he headed the CNS research at BASF AG and Knoll AG. From 1992 to 1996, he held various research and management positions at BASF AG. Dr. HГ¶ger obtained his Ph.D. in 1991 for the doctoral work performed at the German Cancer Research Center (DKFZ) after having studied biology at the Universities of Kiel and Heidelberg, and as a Fulbright Scholar at the Massachusetts Institute of Technology (Cambridge, USA). PRESENTING COMPANIES Apogenix was founded as a spin-out from the German Cancer Research Center (DKFZ). The company is based in Heidelberg, Germany, and employs currently 27 people. t back :: next u YEAR FOUNDED 2005 8.5m в‚¬ public grants raised SPEAKERS TELEPHONE +49 6221 586080 50m в‚¬ raised in three financing rounds, led by dievini Harald Fricke, M.D./Ph.D., CMO/COO SUPPORTING ORGANISATIONS He joined Apogenix GmbH as CMO and COO in January 2006. Previously, he was responsible for global clinical development at Fresenius Biotech GmbH. Prior to this, he was head of Baxter OncologyвЂ™s clinical development department. From 1996 to 2001 he held various national and international management positions at SmithKline Beecham and GlaxoSmithKline, respectively. Dr. Fricke obtained his M.D. in 1987 after having studied medicine at the University of Aachen and the University LГјbeck. ORGANISERS WELCOME Biomay AG www.biomay.com CONTACT Rainer Henning CEO FINANCIAL SUMMARY Biomay is privately held with a share capital of EUR 14.6 million, exclusively provided by private investors. COMPANY PROFILE TELEPHONE +43-1-7966-296-100 FAX +43-1-7966-296-222 The clinical efficacy of our products is demonstrated under the highest medical standards. We cooperate with leading allergy specialists and industrial partners to revolutionize allergy treatment solutions for the patientsвЂ™ benefit. Manufacturing of our own and our clientsвЂ™ development products complies with the highest quality standards. Additionally, we support our clients by offering highly professional GMP contract manufacturing services. MANAGEMENT Rainer Henning, CEO Karl Fister, CFO Hans Huber, COO Angela Neubauer, Head of Product Development t back :: next u YEAR FOUNDED 1984 We discover and develop recombinant allergy vaccines with a superior efficacy and safety profile. These innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis that we generate in close cooperation with our academic partners. Our technology platform is based on a novel peptide carrier fusion protein approach and is broadly patent protected. Our lead product, the grass pollen allergy vaccine BM32, is currently in phase IIb clinical trials. In addition, we have candidate vaccines for house dust mite, cat dander and birch pollen allergies in preclinical development. PRESENTING COMPANIES EMAIL r.henning@biomay.com Biomay aspires to be a worldwide leader in research, discovery and development of disease modifying allergy therapeutics. Our products will dramatically improve the quality of life of patients by offering long-term cure for their disease. SPEAKERS ADDRESS Vienna Competence Center Lazarettgasse 19/1 A-1090 Vienna Austria SUPPORTING ORGANISATIONS ORGANISERS WELCOME Biotie Therapies Corp. www.biotie.com CONTACT Dr Timo Veromaa President & CEO TELEPHONE +358-2-274 8900 FAX +358-2-2748 910 Cash position (liquid assets): Q3-2012: EUR 41.7 million COMPANY PROFILE Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. ParkinsonвЂ™s disease, AlzheimerвЂ™s disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. BiotieвЂ™s products address diseases with high unmet medical need and significant market potential. BiotieвЂ™s most advanced product, SelincroTM (nalmefene), licensed to Lundbeck A/S, has on 14 December 2012 received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorization of Selincro(TM) for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. In addition, Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant which has successfully completed a Phase 2b study in 420 patients with advanced ParkinsonвЂ™s disease. Biotie shares are listed on NASDAQ OMX Helsinki Ltd MANAGEMENT Management Team Timo Veromaa, President and CEO Ian Massey, COO David Cook, CFO (effective February 25, 2013) Stephen Bandak, CMO Chris Piggott, CBO SUPPORTING ORGANISATIONS Board of Directors: Peter Fellner, Chairman William M. Burns, Merja KarhapГ¤Г¤, Bernd Kastler, Ismail Kola and Guido Magni t back :: next u YEAR FOUNDED 2002; Listing date 31/10/2002 Market cap: ~EUR 200 million PRESENTING COMPANIES EMAIL timo.veromaa@biotie.com Listed on NASDAQ OMX Helsinki Ltd (BTHV1) SPEAKERS ADDRESS Biotie Therapies Corp. TykistГ¶katu 6 FI-20520 Turku Finland FINANCIAL SUMMARY ORGANISERS WELCOME BONESUPPORT AB www.bonesupport.com CONTACT Lloyd Diamond CEO TELEPHONE +46 46 286 53 61 FAX +46 46 286 53 71 Funding will last past cash break-even, which is planned for Q4 2013 COMPANY PROFILE BONESUPPORTвЂ™s mission is to provide an injectable radiopaque bone substitute that has been proven to remodel into bone, with the potential to be combined with other substances and is capable of being delivered percutaneously. Its flagship product platform CERAMENTв„ў is an excellent treatment option to be used as a synthetic bone substitute. It is clinically proven as it has been used in more than 4000 patients. The latest advance in the CERAMENTв„ў platform is CERAMENTв„ўG Gentamicin Eluting Bone Void filler which is indicated for use as an osteobiologic scaffold and will protect the bone healing process in an infectious environment. MANAGEMENT Lloyd Diamond, CEO Mr. Diamond joined BONESUPPORT in January 2012 as the Chief Excecutive Officer. He is a seasoned medical device executive with global experience and has worked in both start up and mature companies. He held positions with leading global companies such as Lumenis, Laserscope, Kyphon and Conmed Linvatec (formerly Zimmer). Mr. Diamond became involved in his profession when he decided he wanted to work in health care, but on the business side. He wanted to help improve health care through product development. He now has 20 years of experience developing and launching disruptive technologies in the health care field. In addition, Mr. Diamond has been involved in several successful company turn arounds. Through his leadership, he helps companies to deliver better patient and health economic outcomes. Ultimately, he makes companies provide new standards of care, therefore creating shareholder value. Mr. Diamond holds a BS Degree in Biochemistry and Marketing as well as an MBA in International Finance from the Thunderbird School of Global Management. BONESUPPORT, under his leadership, received the Red Herring Global Top 100 citing them as one of the top entrepreneurial companies in the world. t back :: next u YEAR FOUNDED 1999 56% of capital was invested by new investors, and 44% by existing investors PRESENTING COMPANIES EMAIL Lloyd.diamond@bonesupport.com pia.carlsen@bonesupport.com The company has raised over в‚¬50M since inception. Most recently it raised EUR 19.2m / SEK 171m (in July 2011) to expand sales and market channels SPEAKERS ADDRESS SCHELEVГ„GEN 19A 223 70 Lund Sweden FINANCIAL SUMMARY Offer Nonhoff, CFO SUPPORTING ORGANISATIONS Offer Nonhoff comes to BONESUPPORT from Lumenis, a world market leader in the medical laser industry, where he was the CFO for the EMEA region for the past 3 years. Beyond finance Offer was also responsible for Human Resources, Sales Administration and Order Processing. Prior to Lumenis, Offer worked for Animation Lab, a start up company in the high tech media space, and for Siemens one of the largest medical and electronic engineering companies in the world. During his fifteen year career at Siemens, Offer rose up through the ranks to become CFO for Siemens Israel. In this role Offer enabled the company to achieve market leadership (with multi-million dollar revenues) in several fields of business, and in the process became ranked in the top 500 in a company with in excess of 500,000 employees. He lead the company to win the bid to implement Tel AvivвЂ™s first light rail system, five power plants of which three are already in operation, and many bids for advanced power transmission and medical imaging technologies. Beginning in Accounts for Siemens in Germany, Offer was promoted to Financial Controller in the networking switching arena in Israel where he subsequently guided all investments, establishing regional offices that represented the entire portfolio of the company in Israel and the Palestinian Autonomy. Working with Siemens Israel from start-up provided Offer the opportunity to perform leadership responsibilities in the areas of corporate management, accounting, controlling, IT and finance. Offer studied in Germany and the U.S., receiving his BA of Industrial Business Administration from the IHK in Munich. ORGANISERS WELCOME Bone Therapeutics SA www.bonetherapeutics.com CONTACT Enrico Bastianelli MD, MBA Chief Executive Officer FINANCIAL SUMMARY Funds raised : 30Mio EUR COMPANY PROFILE Bone Therapeutics is a leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases. Utilizing the CompanyвЂ™s unique knowledge of the bone/joint physiology and long-standing expertise in cell therapy and cell transplantation, Bone Therapeutics has created a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored inhouse production methods and minimally invasive treatment techniques. TELEPHONE +32 (0) 2 529 59 90 Bone TherapeuticsвЂ™ lead product, PREOBВ®, is an autologous bone cell product, currently in Phase III clinical trials for the treatment of osteonecrosis and non-union fractures. Bone Therapeutics is also developing an allogeneic bone cell therapy product, ALLOBВ®, which is expected to enter the clinic in 2013 and MXB, a combined cell-matrix product for the treatment of large bone defects, currently in preclinical development. All of Bone TherapeuticsвЂ™ cell therapy products are manufactured to the highest GMP standards, comply with all regulations and are protected by a rich IP estate. FAX +32 (0) 2 529 59 93 EMAIL info@bonetherapeutics.com MANAGEMENT Enrico Bastianelli MD, MBA, CEO ValГ©rie Gangji MD, PhD, CSO PRESENTING COMPANIES The bone disease and reconstruction market is one of the largest healthcare markets in the world, with more than 4 million procedures requiring bone grafts performed annually in Europe and the USA alone. Bone Therapeutics is operating in areas where demand for new products is high and competition is low. t back :: next u YEAR FOUNDED 2006 SPEAKERS ADDRESS 8, rue Adrienne Bolland 6041 Gosselies BELGIUM SUPPORTING ORGANISATIONS ORGANISERS WELCOME CellMed www.cellmed.at CONTACTS Dr Wolfgang Huber Chief Executive Officer FINANCIAL SUMMARY Dr Marianne Imhof Chief Scientific Officer COMPANY PROFILE TELEPHONE +43 (0) 699 172 494 70 FAX +43 (0) 2732 70512-50 Results from the phase I study in ovarian cancer prove PROCUREВ® to be safe and immunologically active (proof of concept) with a positive trend in clinical efficacy. The autologous dendritic cell therapy is manufactured in a robust manufacturing process with the potential for automation. CELLMED plans to conduct a phase II study in cooperation with one of the best clinical cooperative groups in ovarian cancer and to achieve clinical proof of concept by 2016. MANAGEMENT Wolfgang Huber, MD, MBA, CEO Marianne Imhof, PhD, CSO PRESENTING COMPANIES YEAR FOUNDED 2006 The company is led by an experienced management team and supported by a group of world renowned clinical experts in ovarian cancer. t back :: next u EMAIL wolfgang.huber@cellmed.at CELLMED is an Austrian based biotechnology company developing PROCUREВ®, a high potential dendritic cell vaccine. The niche indication for this platform technology is ovarian cancer which is applicable for all solid tumors in general. SPEAKERS ADDRESS MagnesitstraГџe 1 3500 Krems a.d. Donau Austria CellMed is a non public mainly privately funded company with certain national support grants. SUPPORTING ORGANISATIONS ORGANISERS WELCOME Ciloa, SAS www.ciloa.fr CONTACTS Robert Z. Mamoun, Ph.D. CEO/CSO FINANCIAL SUMMARY Renaud Burrer, Ph.D. Senior Scientist COMPANY PROFILE TELEPHONE + 33 (0) 467 143 997 YEAR FOUNDED 2011 Currently, the challenge to obtain fully native membrane proteins out of cells hampers dramatically the development of therapeutic mAbs against important membrane protein targets (receptors, ion channels, etc.). The disruptive technology of Ciloa allows breaking open this lock by producing not only the perfect membrane antigens but also by providing potent methods to: 1. trigger specific immune response against receptor ectodomains, 2. select efficiently scFv phage library, 3. screen easily mAbs (ELISA), 4. characterize all mAbs-receptor interaction parameters (SPR). More, Ciloa exosomes can help also in drug screening, immuno-therapeutic, therapeutic, diagnostic, and vaccine developments. MANAGEMENT SUPPORTING ORGANISATIONS Robert Z. Mamoun, Ph.D., CEO/CSO Coralie Philippe, Ph. D., CFO Renaud Burrer, Ph. D., Senior Scientist Manuela Lotierzo, Ph. D., Senior Scientist MaГ«lle Prorok-Hamon, Ph. D., Senior Scientist PRESENTING COMPANIES EMAIL rmamoun@ciloa.fr rburrer@ciloa.fr Exosomes are tailored by Ciloa to express any type of membrane proteins (with single or multi-transmembrane domains), at high concentrations, embedded in a membrane, with their: вЂў fully native conformation, вЂў natural post-translational modifications (glycosylation, homo- and hetero-oligomerization, cleavage, etc.), вЂў accessory proteins. t back :: next u FAX + 33 (0) 467 144 286 Ciloa is an innovative company with a patented proprietary technology that provides fully native transmembrane proteins on natural nanovesicles called exosomes. Using these recombinant exosomes Ciloa develops mAbs against challenging targets such as GPCR, Kinase Receptors, Ion Channels and more. Exosomes are small lipid membrane vesicles that are secreted by many cell types, that carry both proteins and RNA and that possess potent immuno-stimulatory functions. SPEAKERS ADDRESS Ciloa, SAS Bat. 24, cc107 Universite Montpellier 2 Place E. Bataillon 34095 Montpellier cedex 5 France Private ownerships. ORGANISERS WELCOME Colby Pharmaceutical Company & SILKI AG CONTACTS Colby European Thomas M. KГјndig MD Colby Pharmaceutical SAB, CoChair FINANCIAL SUMMARY Mobile 078 609 35 36 Phone 04 255 34 71 Colby is an immunology and chemistry-driven drug company developing, marketing, and selling small molecule drugs or biologics modulating inflammation. ColbyвЂ™s novel drugs and vaccines treat disease and inflammatory conditions, especially, cancer, infection and pain. The Company leverages capital from investors and asset outlicenses and sales. Colby continues to acquire, reset and resell clinical stage assets. The Company is accessing data generated from contracts, grants, investments, acquisitions, and in-licensed or reset assets. Colby intends on advancing these drug candidates through the clinic to commercialization, either independently or with a partner. Thomas M. KГјndig MD Colby Pharmaceuticals SAB, Co-chair Colby Pharma US Telephone Co Phone (650) 323-6215 Cell Phone (650) 333-3150 Lab Phone (408) 960-7466 Colby Pharma US EMail tkuendig @colbypharmaceuticals.comknarducy @colbypharmaceuticals.com YEAR FOUNDED 2004 COLBY PHARMA EUROPEAN MANAGEMENT Ken Narducy PhD MBA, Colby Pharmaceutical COO Ken is a biopharmaceutical executive and positioned several companies to increase business value and competitive advantage via R&D, IP generation and commercialization, M&A analysis, and venture funding. He developed new biotech/pharmaceutical business for startups (Oculex, Centaur, St. Charles) and biomedical/chemical products for divisions of Abbott Labs, ScheringPlough, and The Cooper Companies. Ken has completed over $1B in prior transactions,, including bringing colored contact lenses to market. Thomas KГјndig MD, Colby Pharmaceutical SAB CoChair & SILKI AG Chief Scientific Officer SUPPORTING ORGANISATIONS Colby Pharma US Fax Corp Fax (650)644-0440 Lab Fax (408) 960-3822 Colby and collaborators have consistently recorded JVRS-mediated-dose-dependent human cancer patient therapeutic responses, some with anecdotal increases in human patient survival to be confirmed by follow-up Phase II trials. The Company has a significant supply of JVRS-100 clinical grade material ready for initiation of multiple Phase II human clinical trials.. To accelerate the companyвЂ™s growth plans and facilitate its transition to focus on Phase II efficacy data in multiple disease indications, Colby management has secured significant clinical assets, partners, collaborators), and is recruiting additional professional staff and new collaborators. PRESENTING COMPANIES Colby Pharma US Address 5941 Optical Court San Jose, CA 95138 Immune Modulator Biologics US Based Division In September, 2011, the immune modulator-biologics division of Colby was formed via a worldwide exclusive in-license acquisition of all the human health assets of Juvaris BioTherapeutics from KPCB (Kleiner Perkins Caulfield Byers), SV Life Sciences, and Abbott Bioventures (see 2011 press releases). ColbyвЂ™s immune modulator division is expecting to enter additional new Phase II hematology and oncology clinical trials. In addition ColbyвЂ™s standalone immune activators or adjuvants for disease specific antigen vaccines can be synergistic with Intra Lymph Node Immunization, ILNI, including protocols being developed with assets from the Colby Pharmaceutical subsidiary, SILKI AG, ZГјrich. t back :: next u ADDRESS Colby European Colby Pharmaceuticals SAB Gloriastrasse 31, 8091 ZГјrich Switzerland COLBY PHARMA COMPANY PROFILE SPEAKERS Colby Pharma US Ken Narducy PhD MBA Colby Pharmaceutical COO San Jose California, USA-based Colby Pharmaceutical Company, is a Delaware C Corporation in good standing in DE and CA. ORGANISERS WELCOME Covagen AG www.covagen.com CONTACTS Dr Julian Bertschinger Chief Executive Officer Dr Dragan Grabulovski Chief Scientific Officer ADDRESS Covagen AG Wagistrasse 25 Schlieren, 8952 Switzerland TELEPHONE +41 44 732 46 60 YEAR FOUNDED 2007 Covagen develops bispecific FynomAbsв„ў by fusing its human Fynomerв„ў binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomersв„ў to multiple sites on an antibody allows Covagen to create FynomAbsв„ў with tailored architecture to maximize efficacy. CovagenвЂ™s lead program is a bispecific TNF/IL-17 inhibitor (in preclinical development) for the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis and rheumatoid arthritis. MANAGEMENT Board of Directors Franz Hefti, Chairman Ray Hill, Anja KГ¶nig, Gilles NobГ©court, Mounia Chaoui, Jon Hepple, Julian Bertschinger Scientific Advisory Board Greg Winter, Ulrich Feige, Thierry Hercend, Christoph Heusser, Christoph Lengauer PRESENTING COMPANIES EMAIL info@covagen.com COMPANY PROFILE t back :: next u FAX +41 44 732 46 64 Investors: вЂў Novartis Venture Fund вЂў Edmond de Rothschild Investment Partners вЂў Ventech вЂў Seroba Kernel Life Sciences вЂў MP Healthcare Venture Management SPEAKERS Dr Fabian Buller Director Business Development FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME Cristal Delivery B.V. www.cristaldelivery.com CONTACT Dr Cristianne Rijcken Chief Executive Officer TELEPHONE +31 30 430 0222 EMAIL Cristianne.rijcken @cristaldelivery.com Joost.holthuis @cristaldelivery.com COMPANY PROFILE Cristal Delivery is a pharmaceutical company that develops first-in-class nanomedicinal products on the base of its proprietary polymeric technologies (CriPecВ®). CriPecВ® enables the development products with a clear competitive edge as a result of their anticipated superior efficacy and improved tolerability profile. The customisable platform allows for an improved disposition of the entrapped drug, preferential accumulation of CriPecВ® in tumour and inflammatory sites, the possibility to be combined with ligands for active targeting and is easily manufactured. CriPecВ® is a unique approach to transform drugs into nanomedicines of around 70 nm and which possess multiple beneficial properties resulting in an improved efficacy and safety profile as already demonstrated in various preclinical studies. Both small molecules and peptides can be combined with CriPecВ® which comprises all key factors for a successful drug: it allows for tailor-made products that take the (physico)chemical properties of the drug, the desired concentration at the target site and the route of administration into account. 2012 was a really exciting year as noteworthy progress has been made in the development of CriPecВ® as well as the first product. Last year milestones were: вЂў Development of sophisticated GMP-manufacturing process of CriPecВ® nanoparticles вЂў Generation of highly promising in vivo efficacy and safety data with CriPecВ® docetaxel when compared with Taxotere вЂў Expansion of CriPecВ® approach to peptides: increasing the in vivo half-life time 50-fold. Dr Cristianne Rijcken, CEO Dr Joost Holthuis, Executive Director SUPPORTING ORGANISATIONS MANAGEMENT PRESENTING COMPANIES The combination of CriPecВ® вЂ�s enabling technology with new or existing drugs will expand opportunities in various therapeutic areas. The resulting products will also open up new areas in diseases that have been so far hard to treat. The company strategy is to leverage its technologies by building a small product portfolio for various indications. A first clinical trial is scheduled with CriPecВ® docetaxel early 2014. Next, Cristal Delivery is actively pursuing strategic partnerships with pharmaceutical companies to conduct custom-made feasibility studies to create innovative products with compelling competitive advantages. t back :: next u YEAR FOUNDED 2011 Cristal Delivery has closed in 2012 a financing round with two Dutch VC firms, BioGeneration Ventures and Thuja. The company is presently in the process of raising additional funds that will enable the finalisation of clinical phase I/IIa. SPEAKERS ADDRESS Padualaan 8 3584 CH Utrecht The Netherlands FINANCIAL SUMMARY ORGANISERS WELCOME Cureline, Inc. www.cureline.com CONTACT Olga Potapova, PhD CEO and Scientific Director FINANCIAL SUMMARY Privately owned company. COMPANY PROFILE TELEPHONE +1-650-875-6400 x 221 FAX +1-650-875-6484 Olga Potapova, PhD, CEO and Scientific Director Alexander Lituev, MD, SVP Biospecimen Operations Kathleen Talmadge, SVP Finance and Operations Irina Zaytseva, MBA, VP Business Development t back :: next u YEAR FOUNDED 2003 MANAGEMENT PRESENTING COMPANIES EMAIL Olga-potapova@curelne.com Cureline is a biomarker and diagnostics CRO specializing since 2003 in human biospecimens acquisition and tissue research projects including study design, regulatory affairs, clinical network management, specimen collection and analysis, and complete logistics. Our areas of expertise are oncology, immunology, inflammation, cardiovascular conditions, metabolic conditions, infectious diseases/sepsis/HIV. We collaborate with major clinical centers in Europe, Asia, and the USA and maintain an extensive biorepository of human biospecimens in South San Francisco (USA). Cureline BioPathology (translational histology CLIA/GLP laboratory) provides high-end tissue research services including IHC protocol development, clinical specimens processing and diagnostics, and digital pathology. European clinical outreach group in St. Petersburg (Russia) supports regulatory affairs, patient enrollment and retention services, clinical site relation management, and marketing research. All our managers have advanced degrees and are experienced in clinical trial operations, research and healthcare management and international business development.. SPEAKERS ADDRESS 290 Utah Ave Ste 300, South San Francisco, CA 94080 USA SUPPORTING ORGANISATIONS ORGANISERS WELCOME Domain Therapeutics www.domaintherapeutics.com CONTACTS Mrs Aurelie Maisner CEO Assistant Dr Marjorie Sidhoum Business Manager TELEPHONE +33 39 040 6150 FAX +33 39 040 6155 2012 вЂ“ 2.0mв‚¬ COMPANY PROFILE Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform to identify orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. The platform is also able to address difficult GPCRs such as orphans and peptidic receptors. The companyвЂ™s pipeline is composed of new chemical entities ranging from hits to optimized leads targeting hot GPCRs for leading indications such as schizophrenia, ParkinsonвЂ™s disease and diabetes.. MANAGEMENT PRESENTING COMPANIES Pascal Neuville, CEO, CSO Gregory Chapron, CFO Stephan Schann, Head of Research t back :: next u EMAIL contact @domaintherapeutics.com amaisner @domaintherapeutics.com msidhoum @domaintherapeutics.com 2008 вЂ“ 2.1mв‚¬ SPEAKERS ADDRESS BioParc 850 Bld Sebastien Brand 67400 Illkirch France FINANCIAL SUMMARY YEAR FOUNDED 2008 (restart) SUPPORTING ORGANISATIONS ORGANISERS WELCOME Dualsystems Biotech AG www.dualsystems.com CONTACT Dr Andreas J. Schulze CEO COMPANY PROFILE ADDRESS Grabenstrasse 11a 8952 Schlieren Together with our partners, we identify and characterize novel mechanisms of action for drugs using cell based screening assays. FAX +41 44 738 55 05 EMAIL andreas.schulze@dualsystems.com Dualsystems Biotech is a provider of custom screening services for industry and academia, specializing in Yeast two-Hybrid, CaptiVate AP/MS-MS and cDNA Library Construction. In addition, Dualsystems provides kits and reagents for a range of research applications, including protein expression, protein-protein interaction and protein activity measurement MANAGEMENT Dr Andreas J. Schulze, CEO, Business Development, Finance Dr Daniel Auerbach, CEO, Operations Mrs Katrin Rutschmann, Director Services PRESENTING COMPANIES t back :: next u YEAR FOUNDED 2000 SPEAKERS TELEPHONE +41 44 738 50 01 Dualsystems Biotech is a Contract Research Organization in the areas of drug and target profiling and proteomics. We provide innovative and flexible solutions to characterize protein complexes and small molecule вЂ“ target interactions in any cellular setting. SUPPORTING ORGANISATIONS ORGANISERS WELCOME Ennar Pharma AG www.ennarpharma.com CONTACTS Dr Rudi D Neirinckx Chief Executive Officer Dr Peter Burckhardt Board Member TELEPHONE 061 283 8485 EMAIL rudi_neirinckx@hotmail.com COMPANY PROFILE Ennar Pharma was founded in July 2010 to develop a better and safer topical treatment for mild-to-moderate psoriasis. Patents, protecting the technology, have been granted in Europe and the USA. The company is financially supported by an investment by EVA- a Basel based venture capital company- and has developed the production of pure EGF and a stable cream-based pharmaceutical product. The cGMP production of high-quality EGF (epidermal growth factor) is carried out by a third-party collaborator. The IMPD for the topical product is Swissmedic-approved and the Proof-of-Concept trial is running at the Dermatology Clinic of the University of Zurich. The trial, which is carried out with mild-to-moderate psoriasis patients, aims to establish the validity of the mode-of-action proposed for the EGF-based topical formulation and test the optimised formulation for clinical efficacy and safety. Results of the trial are expected by the end of Q1 2013. MANAGEMENT PRESENTING COMPANIES Dr Rudi D Neirinckx, Chief Executive Officer Dr Peter Burckhardt, Board Member t back :: next u YEAR FOUNDED 2010 The company is financially supported by an investment by EVA- a Basel based venture capital company and by the private funds of the founder. SPEAKERS ADDRESS Hochbergerstrasse 60c CH-4057 Basel Switzerland FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME Epigenomics AG www.epigenomics.com CONTACT Antje Zeise Manager IR | PR FINANCIAL SUMMARY ADDRESS Epigenomics AG Kleine PrГ¤sidentenstr. 1 10178 Berlin Germany COMPANY PROFILE Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The CompanyвЂ™s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. EpigenomicsвЂ™ lead product, Epi proColonВ®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The CompanyвЂ™s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A. FAX +49 30 24 34 5 - 555 MANAGEMENT EMAIL contact@epigenomics.com The team is headed by Dr. Thomas Taapken (formerly Biotie Therapies, Deutsche Venture, Burrill & Company). Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the U.S. and Europe. PRESENTING COMPANIES Dr Thomas Taapken, CEO/CFO t back :: next u YEAR FOUNDED 1998 SPEAKERS TELEPHONE +49 30 24 34 5 - 0 Epigenomics is publicly listed at the Frankfurt Stock Exchange, Prime Standard: (ECX, ISIN DE000A1K0516). For financial information please refer to the Investor Relations section of the CompanyвЂ™s website. SUPPORTING ORGANISATIONS ORGANISERS WELCOME ERA BIOTECH S.A. www.erabiotech.com CONTACTS Dr Miriam Bastida CBO FINANCIAL SUMMARY Mr DГdac Marco Business Developer COMPANY PROFILE ADDRESS Parc CientГfic de Barcelona C.Baldiri i Reixac, 15-21 - 08028 Barcelona, Spain We call ourselves a science-based commercial organization and are with 20 highly educated, international scientists and product developers, based in Barcelona at the Science Park Privately held. ERA BIOTECHВ® is a mid-size biotechnology company, developing break-through innovations for existing enzymes and step-changes for novel recombinant protein and DNA vaccines. SPEAKERS Please, visit at http://www.erabiotech.com MANAGEMENT TELEPHONE Office: +34 93 403 47 73 Mr Lieven De Smedt, CEO Dr Miriam Bastida, CBO Dr Pau MarzГЎbal, IP Manager FAX +34 93 403 47 72 PRESENTING COMPANIES YEAR FOUNDED 2002 t back :: next u EMAIL contact@erabiotech.com mbastida@erabiotech.com dmarco@erabiotech.com SUPPORTING ORGANISATIONS ORGANISERS WELCOME Glycotope www.glycotope.com CONTACTS Steffen Goletz CEO/CSO FINANCIAL SUMMARY Franzpeter Bracht CFO/CBO COMPANY PROFILE Total investment в‚¬125m. FAX + 49 30 9489 2630 MANAGEMENT EMAIL info@glycotope.com YEAR FOUNDED 2001 Dr Steffen Goletz, CEO/CSO, Founder вЂў CEO/Co-Founder of Nemod GmbH (merged to Glycotope) вЂў Ph.D. in Biochemistry вЂў Scientific Career: Max-DelbrГјck-Centre for Molecular Medicine (Berlin), MRC Centre for Protein Engineering (Cambridge, UK), German Cancer Research Centre (Heidelberg) Dr Franzpeter Bracht, CFO/CBO вЂў AplaGen GmbH, Co-Founder & former CEO/CFO вЂў Co-Founder and Investor in other small Biotechs вЂў Kienbaum Management Consultants Principal, Head of Pharma & Life Sciences вЂў Ernst &Young, Consultant PRESENTING COMPANIES In addition, two second generation antibodies are exhibiting superior features as compared to their originals: the 2 most advanced, CetuGEX, a 2nd generation Cetuximab and TrasGEX, an improved Trastuzumab will enter phase II in Q3/2013. FSH-GEX finished Phase II in Q3/2013 and will start Phase III in Q1 2014. SPEAKERS TELEPHONE + 49 30 9489 2600 Marcel Kuehnert Operations t back :: next u ADDRESS Glycotope GmbH Robert-Roessle-Str. 10 13125 Berlin Germany GLYCOTOPE GmbH is a German biotech company founded in 2001 with new technologies and 4 phase I/II products. Today the company has more than 150 employees at two sites in Berlin and Heidelberg and a total investment of в‚¬125m. First product comes out of a technology developing new antibodies against glyco-targets (GlycoBodies). With GlycoExpress, we own a novel and regulatory approved system based on human cell lines that confers a fully human and, if desired, an optimized glycosylation, leading to higher activity, prolonged half life time and reduced immunogenicity. Using this technology, GLYCOTOPE develops NBEs and second generation antibodies and other non-antibody proteins, such as GT-MAB 2.5-GEX, a monoclonal antibody (GlycoBody) that recognizes a combination of its target protein backbone as well as the attached glycosylation, leading to extremely specific target recognition combined with a high binding affinity. PankoMab is scheduled to proceed to phase II in ovarial cancer in Q2/2013. SUPPORTING ORGANISATIONS ORGANISERS WELCOME GRL Inc. www.grl-inc.com CONTACTS Mike Ghias CEO FINANCIAL SUMMARY David Evans CSO COMPANY PROFILE TELEPHONE +301-740-1730 FAX +301-740-1731 PRESENTING COMPANIES YEAR FOUNDED 2006 AnaViRx (founded in 2013) has inlicensed worldwide rights for development of a novel orally available therapeutic against Influenza A and B. This small molecule is easily manufactured, has a good safety profile and has demonstrated a 50% reduction in the time for symptoms in flu in patients with type A or type B infection with a reduction in viral load in these patients. The compound has shown efficacy against a wide array of flu strains (including H1N1, H3N2 and H5N1). We are seeking partners and/or funding to drive clinical development of these molecules through USFDA and EMEA. t back :: next u EMAIL mghias@grl-inc.com devans@grl-inc.com GRL has founded, acquired and built companies focused in detection, diagnosis and therapeutic treatment of disease. The company has partnership relationships with CustomArray Inc (Semiconductor based microarray platform for rapid disease/biothreat detection and identification вЂ“ privatized from Combimatrix), founded AnaViRx Inc (orally available antiviral that has shown excellent efficacy against Influenza A and B through novel mechanism) and was an angel investor in Sirnaomics (siRNA therapeutic development using proprietary nanoparticle delivery systems). SPEAKERS ADDRESS Suite 130 401 Professional Dr., Gaithersburg, MD 20879 USA GRL is privately held. SUPPORTING ORGANISATIONS ORGANISERS WELCOME Helsinn Healthcare SA www.helsinn.com CONTACT Roberto De Ponti Head of Corporate Business Development FINANCIAL SUMMARY ADDRESS Helsinn Healthcare SA Via Pian Scairolo, 6912 Lugano-Pazzallo Switzerland Helsinn GroupвЂ™s Staff: Total = 455 Switzerland = 277 Ireland = 141 USA = 37 TELEPHONE +41 91 985 21 21 Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. HelsinnвЂ™s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. HelsinnвЂ™s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at HelsinnвЂ™s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. YEAR FOUNDED 1976 COMPANY PROFILE Further information on Helsinn Group is available at www.helsinn.com. MANAGEMENT SUPPORTING ORGANISATIONS Dr Gabriele Braglia, Founder & Chairman Dr Riccardo Braglia, Helsinn Group CEO, Board Member & US Chairman Dr Luigi Caletti, Group Chief Financial Officer, Board Member & US Board Member Dr Giorgio Calderari, Group General Manager & Chief Operating Officer & US Board Member Dr Roberto De Ponti, Senior Director, Head of Corporate Business Development Dr Andrea Meoli, Chief Commercial Officer Dr Sergio Cantoreggi, Chief Scientific Officer Dr Matteo Missaglia, Senior Director, General Counsel, Corporate Legal Affairs Dr Daniele Bonadeo, Senior Director, Head of Corporate Technical Dr Paolo Guainazzi, Local General Manager, Chemical Business, Helsinn Advanced Synthesis Dr Padraig Somers, Local General Manager, Pharma Business, Helsinn Birex Pharmaceuticals, Ireland Dr William Mann, Local President & CEO & Board Member US Pharma Business, Helsinn Therapeutics (U.S.), Inc. t back :: next u EMAIL info-HHC@helsinn.com rp@helsinn.com Helsinn GroupвЂ™s R&D Investments in last 5 years: CHF 298.5M PRESENTING COMPANIES FAX +41 91 993 21 22 Helsinn GroupвЂ™s 2011 Total Assets: CHF 436.1M вЂ“ EUR 359.2M SPEAKERS Roberto De Ponti Direct line: +41 91 985 21 21 Helsinn GroupвЂ™s 2011 Total Net Turnover: CHF 300.2M вЂ“ EUR 243.9M ORGANISERS WELCOME HemaCore LLC www.hemacore.com CONTACT Anna Dushina TELEPHONE + 7 495 258 25 38 FAX +7 499 152 37 54 Company raised $19M round A financing in 2010 from Rusnano and Sberbank Capital. Currently company finished the development, started serial manufacturing and started sales in Russia. HemaCore looks for round B in 2013 for GCP clinical trials in Europe and CE-IVD certification. COMPANY PROFILE HemaCore LLC is a biotech company, developing medical devices and methods for hematology. The main product is Thrombodynamics вЂ“ a new global assay for blood clotting monitoring and anticoagulant control, which is highly sensitive to hypercoagulation. Thrombodynamics analyser and disposables sales in Russia started in November 2012. SPEAKERS ADDRESS 3, 4th 8 Marta street, Moscow 125319, Russia FINANCIAL SUMMARY MANAGEMENT Igor Pivovarov, CEO вЂў Physicist, Physics department MSU EMAIL mail@hemacore.com вЂў Physicist, Physics department MSU Fazly Ataullakhanov, CTO Michail Panteleev, CSO вЂў Dr.Sc., PhD, Prof вЂў Moscow State University вЂў Chief of laboratory of molecular mechanisms in CTP PCP RAS Ilya Serebriysky, CMO вЂў MD, hematologist PRESENTING COMPANIES вЂў Dr. Sc., PhD, Prof. вЂў Moscow State University вЂў Head of blood biochemical laboratory HSC RAS t back :: next u YEAR FOUNDED April 2010 Andrey Kondratovich, COO SUPPORTING ORGANISATIONS ORGANISERS WELCOME Heptares Therapeutics Ltd www.heptares.com CONTACT Malcolm Weir Chief Executive Officer FINANCIAL SUMMARY ADDRESS Heptares Therapeutics Ltd BioPark Broadwater Road Welwyn Garden City Hertfordshire AL7 3AX COMPANY PROFILE TELEPHONE +44 (0)1707 358 629 (dl) +44 (0)7968947268 (m) Our in-house pipeline is led by our selective muscarinic M1 programme for cognition in AlzheimerвЂ™s disease and Schizophrenia, which is in preclinical development and slated for Phase 1 studies in 2013. Our adenosine A2a antagonist candidate, licensed to Shire, is also in development for neurological disorders. Further discovery programmes include oral GLP-1 agonists for T2DM, driven by our proprietary first-ever Family B crystal structure, and CGRP antagonists for prophylaxis and treatment of migraine. PRESENTING COMPANIES YEAR FOUNDED 2007 The Heptares technology platform represents a unique GPCR capability in the industry today, opening up new possibilities for both small molecule and antibody therapeutics across the GPCR target universe. Heptares is the first and only company transforming GPCRs, which are typically highly unstable when removed from cellular membranes, into stabilised receptors or StaRsВ®. StaRsВ® enable GPCR structures in their natural pharmacological conformations to be determined, thereby overcoming a major historical barrier to structurebased GPCR drug discovery. Heptares has also invented Biophysical Mappingв„ў, which provides superior elucidation of GPCR-ligand interactions, and has engineered new fragment-based and in silico technologies specifically tailored to GPCR lead discovery and optimisation. These technology breakthroughs, coupled with deep expertise in GPCR chemistry and biology, form the nucleus of a powerful and fully-integrated drug discovery platform. t back :: next u EMAIL malcolm.weir@heptares.com Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including AlzheimerвЂ™s disease, ParkinsonвЂ™s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes. SPEAKERS FAX +44 (0)1707 35840 $40M venture finance to date from Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund and Takeda Ventures. To learn more about the Heptares pipeline and technology platform, please visit www.heptares.com MANAGEMENT SUPPORTING ORGANISATIONS Dr Malcolm Weir, Co-Founder and CEO Dr Fiona Marshall, Co-Founder and CSO Dr Barry Kenny, CBO Dan Grau, President Dr Miles Congreve, VP Chemistry Dr David McGibney, CMO and Head of Development ORGANISERS WELCOME immatics biotechnologies www.immatics.com CONTACTS Mark Bleckmann Director & Head of Finance Nikola Wiegeler Communications TELEPHONE +49 7071 5397-0 immatics successfully concluded a total of three financing rounds, raising a total of в‚¬108m. The company is backed by a particularly strong investor group, comprised of family offices and VCs. COMPANY PROFILE immatics is a clinical stage biopharmaceutical company, active in the field of cancer immunotherapy. immatics is developing TUMAP-based (=Tumor Associated Peptides) therapeutic vaccines that are active against cancers with a high unmet medical need. Three product candidates, all of which were developed with its proprietary technology platform XPRESIDENTв„ў are currently in clinical development. Phase II results from its products IMA901 in RCC and IMA910 in CRC showed a correlation of the number of peptides that patients responded to and the clinical benefit these patients experienced. The furthest advanced product, IMA901 in RCC, is presently in a clinical Phase III trial, which is fully recruited. All of immaticsвЂ™ current products are off the shelf products. SPEAKERS ADDRESS immatics biotechnologies GmbH Paul-Ehrlich-StraГџe 15 72076 Tuebingen Germany FINANCIAL SUMMARY Please visit our website at www.immatics.com to find out more about immatics. MANAGEMENT FAX +49 7071 5397-900 PRESENTING COMPANIES YEAR FOUNDED 2000 t back :: next u EMAIL info@immatics.com Paul Higham, CEO Harpreet Singh, CSO Carsten Reinhardt, CMO Rainer Kramer, CBO SUPPORTING ORGANISATIONS ORGANISERS WELCOME Immune Pharmaceuticals www.immunepharma.com CONTACTS Daniel Teper Anna Baran USA: 1120 Avenue of the Americas, 14th Floor New York, NY 10036 TELEPHONE Israel: +972-9 8866612 USA: +646-588-5430 IMMUNE pipeline includes: вЂў Bertilimumab Ulcerative Colitis, Severe Asthma, Bullous Pemphigoid, VKC вЂ“ Phase II вЂў Ferritin targeted combo Gem-Pac NanomAbs EPICEPT pipeline includes: вЂў AMIKET Chemotherapy Induced Peripheral Neuropathy вЂ“ Phase III вЂў Azixa вЂ“ Brain Tumors вЂ“ Phase II вЂў Crolibulin вЂ“ Solid Tumors вЂ“ Phase II TECHNOLOGY NanomAbs are conjugates of drug loaded nano-particles and monoclonal antibodies, a novel alternative to Antibody Drug Conjugates. They allow targeted delivery of anti-cancer agents to tumor cells. This technology was developed by Professor Benita at Hebrew University of Jerusalem and has been licensed by IMMUNE from YISSUM. IMMUNE is advancing its own candidates toward the clinic. IMMUNE is also making the technology available as part of co-development agreements. Dr Daniel Teper, Chairman and CEO Dr David Sidransky, Vice Chairman of the Board Robert Cook, will become the combined companyвЂ™s CFO Suzy Jones, Chief Business Development Officer Dr Isaac Kobrin, Board Member Dr Stephane Allard,CMO Serge Goldner, SVP & COO Dr Oshrat Frenkel, Director of Research SUPPORTING ORGANISATIONS MANAGEMENT PRESENTING COMPANIES YEAR FOUNDED 2010 Status t back :: next u EMAIL Daniel.teper@immunepharma.com Anna.baran@immunepharma.com IMMUNE Pharmaceuticals is a global clinical stage bio-pharmaceutical company resulting from the merger of a privately held Israeli company, and EpiCept Corporation (вЂњEpiCeptвЂќ) (NASDAQ OMX Stockholm Exchange and OTCQX: EPCT). The combined company is focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. IMMUNEвЂ™s lead product candidate, BERTILIMUMAB, is a first in class fully human monoclonal antibody that targets eotaxin-1, a chemokine involved in eosinophilic inflammation, angiogenesis and neurogenesis. Immune has initiated a placebo-controlled, double-blind Phase II clinical trial with bertilimumab for the treatment of ulcerative colitis and plans to initiate in 2013 additional clinical studies in severe asthma, in bullous phemphigoid, a dermatological orphan condition and in Verneal Kerato-conjunctivitis, an ocular orphan condition. The companiesвЂ™ collective oncology portfolios comprise: ImmuneвЂ™s NanomAbsВ®, a new generation of antibody drug conjugates, and EpiCeptвЂ™s vascular disruptive agents. Immune Pharmaceuticals will continue efforts to secure a development partner for EpiCeptвЂ™s Phase III clinical development candidate AmiKetв„ў, for which the FDA has granted Fast Track designation for the treatment of chemotherapy-induced neuropathic pain SPEAKERS ADDRESS Israel: Aba Even 15, Herzliya COMPANY PROFILE ORGANISERS WELCOME Immunovaccine Inc. www.imvaccine.com CONTACTS John J. Trizzino Chief Executive Officer FINANCIAL SUMMARY Vicki Morgan VP, Business Development Recent share price: $0.37 TELEPHONE 902-492-1819 FAX 902-492-0888 Average Daily Volume: 32,000 Cash & Other Cash Resources (30/09/12): $3.6M COMPANY PROFILE Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The CompanyвЂ™s DepoVaxв„ў platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccines through Phase I clinical trials. These trials were successfully completed demonstrating both safety and immunogenicity potential in two cancer vaccine programs. Immunovaccine is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations with corporate, academic, and government partners. In addition to the CompanyвЂ™s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the CompanyвЂ™s delivery technology platform to develop vaccines for livestock. MANAGEMENT John J. Trizzino, CEO Vicki Morgan, VP, Business Development Kimberly Stephens, CFO Marc Mansour, Ph.D., CSO SUPPORTING ORGANISATIONS Board of Directors Albert Scardino, Chairman, Communications Strategist, Pulitzer Prize Recipient William Cochrane, MD, 2010 Inductee Canadian Medical Hall of Fame Wade Dawe, CEO of Brigus Gold James Hall, CA, Sr.VP of Investments GrowthWorks Stephanie LГ©ouzon, Senior Advisor to Torreya Partners Wayne Pisano, Former President and CEO of Sanofi Pasteur Brad Thompson, CEO of Oncolytics PRESENTING COMPANIES YEAR FOUNDED 2000 52 Week Range: $0.20 вЂ“ $0.45 t back :: next u EMAIL jtrizzino@imvaccie.com vmorgan@imvaccine.com Recent Market Cap: $23.5M SPEAKERS ADDRESS 1344 Summer Street, Suite 412 Halifax, Nova Scotia B3H 0A8 CANADA Shares outstanding: 63.5M ORGANISERS WELCOME Implandata Ophthalmic Products GmbH www.implandata.com CONTACT Max G. Ostermeier CEO TELEPHONE +49 511 2204 2581 в‚¬3.7m raised in seed and series A round. Currently the company is going to raise a в‚¬5m serious B round for market launch in Europe and US regulatory approval. First revenues are expected in 2014, profitability in 2016. COMPANY PROFILE SPEAKERS ADDRESS Kokenstrasse 5 0159 Hannover Germany FINANCIAL SUMMARY Implandata is a medical device start-up company, developing ophthalmic products for monitoring and improved management of glaucoma patients. Reduction of intraocular pressure (IOP) is the main goal of any glaucoma therapy. By continuous monitoring of IOP, therapy and compliance of glaucoma patients can be dramatically improved. EMAIL info@implandata.com mostermeier@implandata.com The company has developed an implantable micro sensor, which is continuously and telemetrically monitoring the IOP. The measured data is sent to an external device for data display and storage. This data is sent to the eye doctorвЂ™s office via tele-medical integration. YEAR FOUNDED 2010 The company is currently conducting clinical studies for attaining CE mark for its first product in 2013. Thereafter the company will perform a first launch in Europe. Regulatory approval for the US market is expected in 2015, followed by the market launch. The company has further products in the R&D pipeline and can trust on a sound IP position and collaboration with prestigious sites and world class clinicians and scientists. MANAGEMENT Max G. Ostermeier, CEO Stefan Meyer, CTO Prof. Robert N. Weinreb (UCSD), Head of SAB PRESENTING COMPANIES 24h IOP measurements and measurement between office visits will reveal vital IOP information on the therapy outcome and ensure early on вЂњtitrationвЂќ of therapy. Remote patient management allows more efficient patient care. t back :: next u FAX +49 511 2204 2589 SUPPORTING ORGANISATIONS ORGANISERS WELCOME Insuline-Medical Ltd www.insuline-medical.com CONTACT Mr Ron Nagar President & CEO TELEPHONE +972-3-9301094 FAX +972-3-9341094 We have recently submitted our FDA application for the infusion pump device (InsuPatch). We have recently published Interim results from large study conducted with device for insulin injections (InsuPad) in Germany. This study was planned with the BARMER sick fund for purposes of reimbursement. The primary end point was reduction in prandial Insulin dose when the InsuPad device is used. The interim analysis showed reduction of about 30% in prandial insulin dose between test and control groups. We have CE mark for our products and we are building independent go-to-market ability in Germany first, to be expanded later on, to Europe and the US. In preparation for launching the injection product in Germany we have formed a fully owned subsidiary (InsuLine-Medical GmbH), and are gearing up towards manufacturing and pre-marketing studies. MANAGEMENT Ron Nager, President & CEO David Ben-Naim, CFO Gabriel Bitton, VP R&D Noam Kfir, VP Operations t back :: next u YEAR FOUNDED 2007 The technology, while seemingly straight forward requires balancing blood perfusion effectiveness while also avoiding overheating the insulin itself above the allowed threshold. It is protected by pending patents globally, and involves significant device knowhow. PRESENTING COMPANIES EMAIL ron@insuline-medical.com Insuline Medical Ltd. is a Public Israeli company (TASE вЂ“ INSL) focused on improving the performance of current insulin treatment methods for diabetic subjects, by trying to better approximate human physiology. Even with todayвЂ™s rapid acting insulin analogs, injected insulin kinetics is still slow compared to normal physiology. Our solutions are disposable devices which treat with heat the point of injection, in order to improve and stabilize blood perfusion. It can be integrated into catheters used with insulin pumps, or as a standalone disposable compatible with syringe or pen delivery. SPEAKERS ADDRESS 70 Pinsker Street P.O.Box 10299 Petach Tikva Israel 4900202 COMPANY PROFILE SUPPORTING ORGANISATIONS ORGANISERS WELCOME i-Optics www.i-optics.com CONTACTS Jeroen Cammeraat Chief Executive Officer FINANCIAL SUMMARY Tanja Hubert PA COMPANY PROFILE TELEPHONE +31 70 399 3112 EMAIL J.Cammeraat@i-Optics.com T.hubert@i-Optics.com EasyScan (CE, FDA cleared). A fast and easy to use retinal imaging system based on SLO technology for the diagnosis of diabetic retinopathy, age-related macular degeneration and glaucoma. Cassini (CE, FDA cleared). A first of its kind corneal topographer based on the principle of color LED topography (CLT), that supports premium contact lens fitting and planning of refractive and cateract surgery (IOL placements). EyePrevent. An integrated service for screening diabetes patients and others for retinal diseases that could lead to blindness. MANAGEMENT PRESENTING COMPANIES Jeroen Cammeraat, CEO Thomas van Elzakker, COO Egbert Houwer, CFO t back :: next u YEAR FOUNDED 2007 i-Optics is a leading pioneer in smart and superior eye diagnosis solutions. Our products are designed to be affordable, fast and easy to use by care providers all over the world to better serve patients in the most convenient way. We sell our products through our direct sales force in Netherlands, Germany and USA and have distributors in other key markets. Our product portfolio includes: SPEAKERS ADDRESS Mauritskade 35 2514 HD Den Haag Netherlands Not disclosed. SUPPORTING ORGANISATIONS ORGANISERS WELCOME Juventas Therapeutics, Inc. www.juventasinc.com CONTACT Rahul Aras, Ph.D. President and CEO TELEPHONE +216 273 4000 FAX +216 359 0099 EMAIL rahul@juventasinc.com COMPANY PROFILE Juventas Therapeutics is a clinical-stage regenerative medicine company developing novel therapies for ischemic disease. The companyвЂ™s lead product, JVS-100, is a non-viral plasmid that encodes for stromal cellderived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival, recruiting endogenous stem cells to the damaged region, and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems including the heart, brain, kidney, dermis, vasculature, and nervous system providing the opportunity to impact a broad range of diseases. Target clinical indications address large markets with high unmet medical need and significant market potential. MANAGEMENT Rahul Aras, Ph.D., President and CEO Marc Penn, M.D., Ph.D., Chief Medical Officer Joseph Pastore, Ph.D., Vice President, Product Development Paul Resnick, M.D., Vice President, Business Development PRESENTING COMPANIES In 2012 the company initiated two Phase II clinical trials for use of JVS-100 to treat patients with critical limb ischemia (CLI) and to treat patients with heart failure (HF). Together, the trials are being conducted at 16 sites in the US and abroad. Phase I study results in patients with heart failure demonstrated that JVS-100 is well tolerated, with patients showing significant improvements in key functional parameters including six minute walk distance (6MWd), Quality of Life (QOL), and NYHA class. Juventas has raised sufficient funds to complete the two Phase II clinical trials. t back :: next u YEAR FOUNDED 2007 The Company has raised $30.2 million in venture funding. Investors include: Triathlon Medical Venture Partners, Fletcher Spaght Ventures, Early Stage Partners, New Science Ventures, Takeda Ventures, Reservoir Venture Partners, Venture Investors, Blue Chip Venture Co., North Coast Angel Fund and JumpStart. The Company has brought in an additional $2.5 million in grant funding through the Ohio BioValidation Fund, Global Cardiovascular Innovation Center, the Center for Stem Cell and Regenerative Medicine, and the QTDP Grant. SPEAKERS ADDRESS 3615 Superior Avenue Suite 4403C Cleveland, OH 44114 FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME KLOX Technologies www.kloxtechnologies.com CONTACTS Dr Lise Hebert President & CEO FINANCIAL SUMMARY Lise Pharand Executive Secretary COMPANY PROFILE ADDRESS 275 Armand Frappier Laval, Quebec H7V 4A7 KLOX Technologies has succeeded in evolving the use of light in therapeutic treatments to a new level. It has developed an innovative technology platform; the KLOX Biophotonic System, which consists of a primary multiLED light device and a topical photo converter gel. The element-rich photo converter gel is applied to the area being treated, which is then illuminated by the lamp. The interactions that take place aid in the creation of an environment favoring repair. TELEPHONE Lise Pharand: 450-680-4571 The innovative Biophotonic System is being evaluated in clinical studies for the treatment of acne, and other medical applications such as wound healing. It has shown itself to be non-abrasive, non-thermal, and noninvasive, with an encouraging safety profile to date. FAX 450-680-4549 KLOX Technologiesв„ў is dedicated to growing commercial activities across varied fields; the sale of the cosmetic dental products to Valeant Pharmaceuticals allows the company to streamline efforts and focus energies on becoming a leader in medical applications in dermatology, wound healing and dental. Invested $25M to date. Based in Canada, KLOX Technologiesв„ў is a privately-owned company currently developing innovative and highly effective therapeutic and cosmetic solutions for use in the fields of Dermatology, Tissue Repair and Dentistry. Acne: completed randomized, controlled split face trial in Europe with results expected in Q1 2013; submission for regulatory approval in Europe for moderate to severe acne expected in Q2 2013. Ready for worldwide or regional partnering Wound Healing: Initiating and completing U.S. and Canadian pressure ulcer Stage II and III pilot study in 2013. Initiating European pressure ulcer Stage III registration trial in 2013 PRESENTING COMPANIES YEAR FOUNDED 2007 Skin Rejuvenation: cleared for commercialisation in US, Europe and Canada and is ready for worldwide or regional partnering SPEAKERS PIPELINE t back :: next u EMAIL lhebert@kloxtechnologies.com lpharand@kloxtechnologies.com Management SUPPORTING ORGANISATIONS Dr Lise Hebert, President & CEO Mariano Rodriguez, VP & Chief of Finance and Operations David Burroughes, Head, Wound Healing Denis Vezina, Head, Clinical Tuba Yamac, Director, IP Eric Desrosiers, Director, R&D Jody Engel, Director, BD Flor del Pilar Arana, Director, Regulatory Isabelle Harvey, Director, Operations ORGANISERS WELCOME Lipopharma Therapeutics www.lipopharma.com CONTACTS VicenГ§ Tur CEO & Co-founder FINANCIAL SUMMARY Prof. Pablo Escriba CSO & Co-founder Lipopharma has so far raised Eur. 7M+ in capital (seed + series A) and research grants and is now looking for 8 million Euros investment to complete PII trials of Minerval in cancer in Europe and US and to start regulatory preclinical development of AD and SCI products. ADDRESS Ctra. Valldemossa, Km.7,4. ParcBIT. Edif.17. 2Вє C-8 07121 вЂ“ Palma de Mallorca. Spain Venture capital, partnership or IPO are currently being considered. FAX +34 97 143 9886 COMPANY PROFILE Other MLT based programs (in preclinical testing) are in AlzheimerвЂ™s disease (AD), Spinal Cord Injury (SCI) and Inflammation. Initial results in two different animal models of AD suggest that LP226A1 has a very significant disease modifying capacity and neurogenesis activity. Lipopharma Inc. was established in Boston area as a US subsidiary in 2011. YEAR FOUNDED 2006 Lipopharma is currently seeking for new partnership opportunities with leading players in the pharmaceutical market in order to complete the clinical development and commercialization of Minerval in oncology and advance our programs in AD and SCI, as well as to further develop the promising MLT based pipeline PRESENTING COMPANIES Lipopharma is a pioneering biopharmaceutical company based in Palma de Mallorca, Spain that is developing a new generation of medicines associated with the Membrane Lipid Therapy (MLT), a novel and unique approach developed by our team of world reputed scientists targeting the membrane lipids of the cell. The lead product, Minerval, regulates the lipid structure and composition of cancer cell membranes through activation of sphingomyelin synthase (SMS), resulting in 1) PKC mild activation, which causes an important reduction of Cyclin D-associated cell proliferation and 2) a normalization of the Ras/MAPK and PI3/Akt signaling pathways, leading to cancer cell differentiation and selective death by autophagy/apoptosis. In pre-clinical studies MinervalВ® has demonstrated very high anticancer activity and lack of toxicity, outperforming the drugs of reference. MIN-0011203, the first clinical PI/IIa study with Minerval in Glioma and other advanced solid tumors has already been authorized by the UK and Spanish Regulatory Agencies and first patients will be enrolled in Q1 2013. t back :: next u EMAIL info@lipopharma.com v.tur@lipopharma.com pablo.escriba@lipopharma.com SPEAKERS TELEPHONE +34 97 143 9886 Lipopharma is a private company founded in 2006, headquartered in Palma de Mallorca, Spain. The company is financed by independent private investors and founders. MANAGEMENT SUPPORTING ORGANISATIONS VicenГ§ Tur, MBA., CEO & Co-founder Prof. Pablo Escriba, Ph.D., CSO & Co-founder Prof. Xavier Busquets, Ph.D., Research Director Grahaem Brown, MD, Ph.D., Development Director (consultant) Marco A. Moreno, Ph.D, QP., Quality and regulatory affairs (consultant) Neil Dey, Ph.D, Development & Director of US operations. ORGANISERS WELCOME Mabimmune Diagnostics AG www.mabimmune.com CONTACT Dr Chad Brokopp Chief Executive Officer TELEPHONE +41 (0)78 901 22 93 FAX +41 44 755 46 47 EMAIL chad.brokopp@mabimmune.com COMPANY PROFILE The Problem: TodayвЂ™s best infarction-prevention medications reduce the risk of cardiovascular death by approximately 20% after one year. Product: InfarctPrevent is a clinical theranostic package consisting of: 1. a human antibody medication anticipated to reduce the risk of infarction by 34% based on pre-clinical trails, and 2. a companion diagnostic blood test that identifies patients who will respond to the treatment. The blood test identifies the enzymatic activity of F17 one of MabimmuneвЂ™s proprietary molecular targets found to significantly contribute to both heart attack and stroke. The medication (FlowMab) is a best-in-class human-derived antibody that neutralizes F17 and is anticipated to significantly lower the risk of infarction. FlowMab is designed to be administered intravenously at a personalized dose determined by the companion diagnostic blood test every 1-3 months. Mabimmune is directed by a team with over 70 years of combined bioentrapreneurial experience and a proven track record of extraordinary value-generation for early biopharmaceutical startups. As an expert in cardiovascular molecular medicine, Dr. Chad Brokopp, PhD (CEO) has discovered MabimmuneвЂ™s target portfolio and contributes 7 years of entrepreneurial experience. Prof. Simon P. Hoerstrup MD, PhD (chairman) is a seasoned expert in cardiovascular medicine and a serial bioentrepreneur who provides clinical and marketing expertise in cardiovascular products and a long-standing expertise in clinical regulatory affairs. Prof. Roger M. Nitsch, MD (board member) is a seasoned bioentrepreneur of several successful corporations and has acquired, negotiated, and executed successful human antibody partnering deals in combined value of over $1bn. Prof. Christoph Hock, MD (board member), has a proven track record of conducting human antibody-based clinical trials. Dr. Jan Grimm, PhD (board member) is a seasoned biopharmaceutical executive who has designed and executed successful business activities for human-derived antibodies and has brought numerous products into lucrative co-development and partnering deals with the worldвЂ™s largest pharmaceutical companies. PRESENTING COMPANIES MANAGEMENT t back :: next u YEAR FOUNDED 2011 The Mabimmune technology was built upon a publically-funded 6 year $1.2 million academic research effort at the University of Zurich. Further Series A financing has been opened to investors in Q1-2013 for raising upper single digit financing for completing pre-IND studies and phase I trials for MabimmuneвЂ™s flagship infarction prevention medication and companion diagnostic. SPEAKERS ADDRESS Wagistrasse 13 8952 Schlieren Switzerland FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME MedGenesis Therapeutix Inc www.medgenesis.com CONTACTS Erich Mohr, Ph.D., R.Psych Chairman & Chief Executive Officer FINANCIAL SUMMARY MedGenesis is privately held. COMPANY PROFILE TELEPHONE +1 (250) 386-3000 FAX +1 (250) 386-3777 MedGenesis Therapeutix (MedGenesis) is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), a minimally invasive technique that provides for targeted, local treatment of CNS conditions such as ParkinsonвЂ™s disease, Epilepsy, Brain Cancer and other severely debilitating diseases of the CNS. MedGenesis lead product GDNF for the definitive treatment of ParkinsonвЂ™s disease is currently in Clinical Phase II. SPEAKERS ADDRESS MedGenesis Therapeutix Inc. 730-730 View Street Victoria, BC, V8W 3Y7 Canada MANAGEMENT Erich Mohr, Ph.D., R.Psych., Chairman & Chief Executive Officer, Founder of MedGenesis Therapeutix Inc. H. Christian Fibiger, Ph.D., Chief Scientific Officer Greg A. Johnson, M.Sc., PMP, FICR, President and Chief Financial Officer MatthiasMatthias Luz, M.D., Chief Medical Officer t back :: next u YEAR FOUNDED 2006 PRESENTING COMPANIES EMAIL info@MedGenesis.com SUPPORTING ORGANISATIONS ORGANISERS WELCOME NeuroPhage Pharmaceuticals www.neurophage.com CONTACTS Hampus Hillerstrom (speaker Executive VP & Chief Financial Officer ADDRESS 222 Third Street Suite 3120 Cambridge, MA 02142 USA TELEPHONE +617-412 5171 YEAR FOUNDED 2007 Series B-1: $9.0M COMPANY PROFILE NeuroPhage is developing a breakthrough platform for treating protein aggregation diseases. The company has a broad pipeline of drug candidates that uniquely target multiple misfolded amyloids (tau, alpha synuclein, amyloid beta, PrP) in several neurodegenerative diseases such as AlzheimerвЂ™s, ParkinsonвЂ™s, ALS and multiple other orphan and ultra-orphan neurology indications such as Creuzfeldt Jacobs disease and tauopathies. The lead drug candidate NPT002, has also shown recently strong activity in an alpha synuclein study sponsored by the Michael J. Fox Foundation and is poised to enter Phase 1 clinical trials in 2014. Based on the discovery of the mechanism of action of NPT002, NeuroPhage is developing second generation Ig fusions displaying the active motif GAIM (General Amyloid Interaction Motif) and has already shown in-vitro and in-vivo efficacy with these compounds. NeuroPhage raised $28.6M since its inception in 2007 with lead investors MГ©rieux DГ©veloppement and Shire LLC. MANAGEMENT Jonathan Solomon, President & CEO Hampus Hillerstrom, EVP & CFO Richard Fisher, Ph.D., CSO Michael Grundman, M.D., Clinical Development Lead Kim Gannon, Ph.D., SVP Preclinical R&D Roxanne Bales, VP Regulatory Jason Right, Ph.D., VP Manufacturing Ram Krishnan Ph.D., Director of Research Haim Tsubery Ph.D., Director of Research PRESENTING COMPANIES EMAIL hhillerstrom@neurophage.com Series B: $12.5M t back :: next u FAX +617-714 5469 Series A: $7.0M SPEAKERS Jonathan Solomon President & Chief Executive Officer FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME Numab AB www.numab.com CONTACT Oliver Middendorp CBO & Co-CEO FINANCIAL SUMMARY Up to CHF 5 million seed money provided through industry collaboration. COMPANY PROFILE TELEPHONE +41 44 533 0471 FAX +41 44 533 0470 NumabвЂ™s technology has been designed to gain mayimal flexibility in antibody-based drug design. This is achieved by engineering highly potent and drug-like antibody variable domains that allow for modular assembly of molecules having the desired pharmacodynamic and pharmacokinetic properties. These may be mono- or bispecific molecules of low (26-50 kDa) or high (150-200 kDa) molecular weight, depending on the targeted product profile. Numab is led by a Management with proven track record in the biotech industry (4 out of 5 Management members have been long lasting employees in key positions at ESBATech). MANAGEMENT David Urech, PhD, CSO & Co-CEO Oliver Middendorp, PhD, CBO & Co-CEO Tea Gunde, PhD, Head of Pharmacology Sebastian Meyer, PhD, Head of Biochemistry Roland Helfenstein, Head of Finance and Administration t back :: next u YEAR FOUNDED 2011 Numab is pursuing two proprietary antibody programs to develop first-in-class therapeutics for autoimmune diseases and pain. Numab has an ongoing multi-target collaboration with Sucampo, under which Numab discovers novel antibody-based development leads. PRESENTING COMPANIES EMAIL o.middendorp@numab.com Numab is a Swiss biotech company that discovers and develops innovative antibody-based therapeutics. SPEAKERS ADDRESS Numab AG Einsiedlerstrasse 34 CH-8820 WГ¤denswil Switzerland SUPPORTING ORGANISATIONS ORGANISERS WELCOME OBS Medical www.obsmedical.com CONTACT Chris Weatherall Head Global QA/RA Director BioQT Bus. Unit Only available on request. COMPANY PROFILE OBS Medical, is a medical device and software innovation company that provides intelligent solutions to hospitals, primary care practices, pharmaceutical, biotechnology and clinical research companies. SPEAKERS ADDRESS Brook House 174 Brook Drive Milton Park Abingdon Oxfordshire OX14 4SD FINANCIAL SUMMARY MANAGEMENT Peter Leyland, CEO Crispin Quail, CFO TELEPHONE 01235 432050 YEAR FOUNDED 2000 t back :: next u EMAIL Chris.weatherall@obsmedical.com PRESENTING COMPANIES FAX 0800 130 3108 SUPPORTING ORGANISATIONS ORGANISERS WELCOME Opexa Therapeutics, Inc. www.opexatherpautics.co.uk CONTACTS Neil K Warma President & CEO TELEPHONE +1 281-775-0600 As of its most recent periodic reporting for the quarter ended September 30, 2012, Opexa had approximately $2.2 million in cash. Opexa recently announced a strategic partnership with Merck Serono which generated an upfront fee of $5 million and potential milestones of $225 million. The company recently priced a private offering which generated $3.25 million in gross proceeds. COMPANY PROFILE SPEAKERS ADDRESS 2635 Technology Forest Blvd The Woodlands TX 77381 USA FINANCIAL SUMMARY Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The companyвЂ™s leading product candidate, TcelnaTM, has the potential to address the significant unmet medical needs of the large multiple sclerosis (MS) patient population. MANAGEMENT FAX +1 281-872-8585 t back :: next u YEAR FOUNDED 2004 PRESENTING COMPANIES EMAIL info@opexatherapeutics.com Neil K. Warma, President & CEO Jaye Thompson, PhD, SVP Clinical Development & Regulatory Affairs Donna R. Rill, SVP Operations & Quality Systems Don Healey, PhD, VP Scientific Development & Manufacturing SUPPORTING ORGANISATIONS ORGANISERS WELCOME Opsona Therapuetics Ltd www.opsona.com CONTACTS Martin Welschof Chief Executive Officer Anne Jensen Executive Assistant TELEPHONE +353 1 677 0223 YEAR FOUNDED 2004 Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, AlzheimerвЂ™s disease and atherosclerosis. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of IrelandвЂ™s leading academic institution with a core focus on immunology research. OpsonaвЂ™s lead product, a fully human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers. The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012. The Company is supported by an international venture consortium including Novartis Venture Fund, Roche Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and Enterprise Ireland. MANAGEMENT Bernd Seizinger, Executive Chairman Martin Welschof, CEO Mary Reilly, VP Pharmaceutical Development & Operations Luke OвЂ™Neill, Co-Founder, Director and CSO Conor Dalton, Finance Director Dr Robert M Miller, Consultant Chief Medical Officer t back :: next u EMAIL mwelschof@opsona.com ajensen@opsona.com COMPANY PROFILE PRESENTING COMPANIES FAX + 353 1 677 8949 Biotechnology Company 0-20 Employees Private Company Latest Round of Funding вЂ“ B Round Funding Total to date вЂ“ $35M SPEAKERS ADDRESS OPSONA Therapeutics Ltd Second Floor Ashford House Tara Street Dublin 2 Ireland FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME Palobiofarma S.L. www.palobiofarma.com CONTACT Dr Julio Castro Palomino Chief Executive Officer TELEPHONE +34 903 402 0815 EMAIL jcastro@palobiofarma.com YEAR FOUNDED 2006 2010 First financing round 2012 Seed financing round 2013 Series A financing round COMPANY PROFILE SPEAKERS ADDRESS Baldiri i Reixac 15-21 08028 Barcelona Spain FINANCIAL SUMMARY Palobiofarma is a biotech company founded in 2006 and based in Barcelona, Spain. The companyВґs mission is to discover and develop new medicines based on the modulation of the adenosine receptors. PalobiofarmaВґs team has designed, synthesized and patented several series of drug-like compounds as adenosine receptor modulators. Starting from this proprietary chemical space, the company has been able to build up a balanced and diversified pipeline, with promising candidates as: PBF-509: A novel potent adenosine A2a receptor antagonist as a best in class treatment of ParkinsonвЂ™s Disease in Phase I clinical trials. PBF-999: A novel potent dual A1/PDE-10 inhibitor as a fist in class treatment for cognitive disorders facing IND-enabling studies. MANAGEMENT Dr Julio Castro Palomino, CEO 15+ years experience in drug discovery in pharmaceutical companies like Bayer and Almirall t back :: next u PBF-695: A novel potent adenosine A3 receptor antagonist as a fist in class oral Glaucoma treatment facing IND-enabling studies. PRESENTING COMPANIES PBF-680: A novel potent adenosine A1 receptor antagonist as a first in class oral asthma treatment in Phase I clinical trials. Dr Juan Camacho, CSO 15+ years experience in projects SUPPORTING ORGANISATIONS ORGANISERS WELCOME ProteoMediX AG www.proteomedix.com CONTACTS Ralph Schiess CEO & Co-Founder Christian Bruehlmann CFO & Co-Founder TELEPHONE +41 44 733 40 90 FAX +41 44 733 40 99 Series A (January 2012): CHF 2.6m (в‚¬ 2.1m) from a group of experienced life science investors. Prize money from various start-up competitions: CHF 250k (в‚¬ 200k). COMPANY PROFILE ProteoMediX is a privately held diagnostic company that was founded in March 2010 as a spin-off company from ETH Zurich. SPEAKERS ADDRESS ProteoMediX AG Wagistrasse 23 8952 Schlieren Switzerland FINANCIAL SUMMARY ProteoMediX enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first products are focusing on prostate cancer, the most frequently diagnosed cancer in men, where neither the detection nor the effective treatment is currently guaranteed. ProteoMediX owns the exclusive commercial rights on a set of protein-based biomarkers that were discovered with state-of-the-art proteomics technology developed at the ETH Zurich. These biomarkers are directly linked to the origin of cancer on a molecular level and allow to capture the complexity of the disease by combining multiple biomarkers. A combination of these showed superior results for the accurate detection of prostate cancer when compared to the current standard PSA test in a clinical proof of concept study. YEAR FOUNDED 2010 Ralph Schiess, CEO & Co-Founder Christian Bruehlmann, CFO & Co-Founder Board of Directors Werner Schaefer, Chairman Isaac Kobrin, Director Wilhelm Krek, Director & Co-Founder Ralph Schiess, Director & Co-Founder Christian Bruehlmann, Director & Co-Founder t back :: next u EMAIL schiess@proteomedix.com bruehlmann@proteomedix.com PRESENTING COMPANIES MANAGEMENT SUPPORTING ORGANISATIONS ORGANISERS WELCOME Resverlogix Corp www.resverlogix.com CONTACT Donald J. McCaffrey President & CEO TELEPHONE +403-254-9252 FAX +403-256-8495 15 MM Cash 25 MM Equity line Market Cap.: 218,178,820 (Feb. 6, 2013) COMPANY PROFILE Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from ResverlogixвЂ™s epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. ResverlogixвЂ™s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Follow us on our blog at http://www.resverlogix.com/blog/ SPEAKERS ADDRESS 202, 279 Midpark Way SE Calgary, AB T2X 1M2 CANADA FINANCIAL SUMMARY Current cash position (as of January 2013) MANAGEMENT t back :: next u YEAR FOUNDED 2001 Donald J McCaffrey, President and CEO, Co-Founder Dr Norman C W Wong, M.D., FRCP, Chief Scientific Officer & Co-Founder A. Brad Cann, CA, Chief Financial Officer Dr Jan O. Johansson, M.D., PH.D., Senior Vice President Medical Affairs Kenneth Lebioda, BA, Senior VP Business & Corporate Development Dr Gregory S. Wagner, PH.D., DABT, Senior VP Research & Development Dr F. Allan Gordon, M.D., PH.D, Senior Vice President of Clinical Development Dr Peter R. Young, PH.D., Senior Vice President of Discovery Research Tina M. Rarick, M.B.A, Vice President of Project Management & Business Operations Dr Henrik C. Hansen, PH.D., Vice President of Pharmaceutical Development PRESENTING COMPANIES EMAIL don@resverlogix.com SUPPORTING ORGANISATIONS ORGANISERS WELCOME R-Pharm www.r-pharm.com CONTACT Vasily Ignatiev Chief Executive Officer 10, Testovskaya st., 123317, Moscow TELEPHONE +7 (495) 956 79 37 +7 (495) 956 79 38 EMAIL info@rpharm.ru Key areas of R-PharmвЂ™s competence include: manufacturing of finished drugs and APIs, R&D of innovative medicines and technologies, training and education for industry and health care specialists, venture investments in promising scientific data and research, cooperation with major international pharmaceutical companies and international universities in the field of drug development and combined clinical trials in Russia. Since foundation not less than 85% of profits reinvested into infrastructure and products development. MANAGEMENT Alexy Repik, Chairman of the Board Vasily Ignatiev, CEO Valery Pereletov, VP, Commercial Affairs Mikhail Samsonov, Chief Medical Officer Alexey Ordzhonikidze, Marketing & Business Development Director Andrey Artemov, Commercial Director Anna Surova, Customer Service Director PRESENTING COMPANIES t back :: next u YEAR FOUNDED 2001 Founded in 2001 in Moscow. Employs over 2600 highly qualified specialists, has 36 branches across Russian Federation and the CIS countries. Turnover reached over $1,6 billion in 2011. SPEAKERS ADDRESS 19-1, Berzarina st., 123154, Moscow COMPANY PROFILE SUPPORTING ORGANISATIONS ORGANISERS WELCOME Scancell Holdings Plc. www.scancell.co.uk CONTACT Dr Richard Goodfellow Chief Executive Officer TELEPHONE 0115 823 1863 FAX 0115 823 1863 Although the study was not designed primarily to measure tumour response, one patient in the 4mg dose cohort with multiple tumour lesions at study entry had a differential response to treatment including partial or complete regression of all lung metastases. A further two patients who had all their tumours surgically removed prior to SCIB1 treatment have remained disease-free more than a year after first dosing. The vaccine produced very few side effects, none of which were serious. These encouraging results provide the first evidence that ScancellвЂ™s ImmunoBodyВ® vaccine approach is producing an immune response in cancer patients which may also be associated with clinical benefit. In view of the positive results and minimal side effects seen with the 4mg dose Scancell intends to evaluate an 8mg dose in parallel with Part 2 of the Phase1/2 study. The ImmunobodyВ® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases. Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Moditopeв„ў platform could have a profound effect on the way that cancer vaccines are developed. MANAGEMENT Professor Lindy Durrant, Joint CEO Dr Richard Goodfellow, Joint CEO t back :: next u YEAR FOUNDED 1997 ScancellвЂ™s first cancer vaccine SCIB1 is a DNA vaccine being developed for the treatment of melanoma. Preliminary results from Part 1 of the Phase 1/2 clinical trial of SCIB1 in patients with Stage III/IV malignant melanoma produced a vaccine induced T cell response to treatment in four out of the six patients treated with either the 2mg or 4mg dose. PRESENTING COMPANIES EMAIL richardgoodfellow@scancell.co.uk Scancell is developing novel therapeutic vaccines for the treatment of cancer based on its groundbreaking ImmunoBodyВ® and Moditopeв„ў technology platforms. SPEAKERS ADDRESS Scancell Ltd Dept Clinical Oncology City Hospital Hucknall Road Nottingham NG5 1PB COMPANY PROFILE SUPPORTING ORGANISATIONS ORGANISERS WELCOME Serpin Pharma www.serpinpharma.com CONTACT Cohava Gelber, PhD, MBA President & Chairman TELEPHONE +1-703 343 3258 EMAIL Gelber@msn.com cgelber@serpinpharma.com YEAR FOUNDED 2010 Serpin Pharma secured its initial funding from private investors in May of 2011 and follow-on financing in April of 2012. In December 2012, Serpin Pharma was awarded a Phase I SBIR grant from the NIH to develop SP16 for type I diabetes. COMPANY PROFILE Serpin Pharma is a privately held biotech company with research facilities in Northern Virginia, USA. The company is developing a family of first-in-class anti-inflammatory and immune modulating peptide drugs derived from human alpha-1-antitrypsin. The peptide drugs have broad application in inflammatory and autoimmune diseases, and potentially represent a superior alternative to alpha-1-antitrypsin in select indications. SPEAKERS ADDRESS 14645 Sulky Run Ct. Nokesville, VA 20181 FINANCIAL SUMMARY TECHNOLOGY Serpin PharmaвЂ™s first-in-class peptide platform was derived from the abundant acute phase protein alpha-1antitrypsin and similar Serpin proteins. The peptide drugs are predicted to control an inflammatory master switch at the interface between the innate and adaptive immune systems. They potentially provide a paradigm shift in disease management, by reducing autoimmunity without the detrimental general immunosuppression induced by some anti-inflammatory drugs. MANAGEMENT PRESENTING COMPANIES Critical safety studies, including hERG assays and human receptor panning studies, predict the SP16 drug will have an excellent safety profile. Serpin Pharma aims to initiate formal, IND-enabling safety studies in 2013 with the goal of starting Phase I Clinical trials in 2014. t back :: next u The lead drug candidate, SP16, is a 17 amino acid peptide and the drug provides protection from disease in mouse models of type II diabetes, rheumatoid arthritis and lethal endotoxemia. Recent data support that SP16 works via the TLR2 receptor, and it is predicted to induce expansion of tolerogenic T-cells (Tregs) and to promote an anti-inflammatory cytokine profile. Cohava Gelber, PhD, MBA, President & Chairman Soren Mogelsvang, PhD, VP of R&D SUPPORTING ORGANISATIONS Scientific and Business Advisors Alexander Fleming, MD, President & CEO at Kinexum Jonathan Zenilman, MD, Chief of the Infections Diseases Division, Johns Hopkins University School of Medicine John Abeles, MD, Venture Investor, Director, Entrepreneur Jacqui Brandwynne, Business strategist, Director ORGANISERS WELCOME Synthena AG www.synthena.com CONTACT Dr Wolfgang Renner Chief Executive Office FINANCIAL SUMMARY Synthena raised over CHF 5 million in a series A founding round. COMPANY PROFILE TELEPHONE +41 79 219 96 70 EMAIL renner@synthena.com YEAR FOUNDED 2012 Synthena AG is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of RNA. Its proprietary tricyclo-DNA technology platform offers broad advantages over state of the art oligonucleotide chemistries for new RNA intervention strategies like splice switching, and other antisense approaches. Its most advanced preclinical drug development program focuses on Duchenne Muscular Dystrophy, a genetic disorder which affects 1/3,500 boys and which leads to death in early adulthood. SPEAKERS ADDRESS Freiestrasse 3 3012 Bern Switzerland Modulation of RNA for therapeutic purposes holds the promise of opening up entirely new concepts for pharmaceutical intervention, however, current oligo-nucleotide chemistries to modulate RNA do not meet the requirements for efficient delivery, pharmacokinetics and tolerability. SynthenaвЂ™s mission is to establish its proprietary tricyclo-DNA technology as the leading platform for RNA modulation. MANAGEMENT Dr Wolfgang Renner, Chief Executive Officer Holds a PhD degree in chemistry since 2005. He was involved in the development and expansion the bicyclo- and tricycloDNA molecular platforms. PRESENTING COMPANIES Dr Branislav Dugovic, Chief Technology Officer t back :: next u Has over 15 years of biotech industry experience as founder and CEO of Cytos Biotechnology AG, where he raised over CHF 270 million, and helped to bring 10 novel product candidates into clinical development of which four are currently in phases I вЂ“ IIb and one is marketed. SUPPORTING ORGANISATIONS ORGANISERS WELCOME Synthon BV www.synthon.com CONTACT Michael Kotsanis Chief Commercial Officer FINANCIAL SUMMARY Revenue in 2012 of в‚¬260 million COMPANY PROFILE TELEPHONE +31 24 372 7700 FAX +31 24 372 7705 Synthon, with headquarters in Nijmegen, the Netherlands is an international fast-growing pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune diseases вЂ“ particularly multiple sclerosis вЂ“ and oncology. Our products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and вЂ“ in dedicated areas вЂ“ through direct sales. Synthon employs about 1,400 staff at 11 sites worldwide, and in 2011 it recorded a turnover of EUR 260 million. SPEAKERS ADDRESS Microweg 22 Nijmegen 6545 CM The Netherlands MANAGEMENT Jacques Lemmens, CEO/Founder Michael Kotsanis, Chief Commercial Officer EMAIL Michael.kotsanis@synthon.com PRESENTING COMPANIES t back :: next u YEAR FOUNDED 1991 SUPPORTING ORGANISATIONS ORGANISERS WELCOME TELORMEDIX SA www.telomedix.com CONTACT Dr Johanna Holldack, MD Chief Executive Officer TELEPHONE +41 (0)91 610 7000 Telormedix founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The CompanyвЂ™s lead product, TMX-101, will shortly commence a Phase II clinical trial for the treatment of CIS (carcinoma in situ) in the bladder. In addition, Telormedix is developing novel TLR7-targeted agonists. One of these molecules, TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. Telormedix also has a pipeline of programs for inflammatory and autoimmune diseases, which includes TMX-302, a TLR7-binding small molecule showing anti-inflammatory properties in vivo. SPEAKERS ADDRESS TELORMEDIX SA Via della Posta 10 CH-6934 Bioggio Switzerland COMPANY PROFILE Located in Switzerland, Telormedix is led by a highly experienced management team and backed by an international consortium of venture capitalists including Aravis Venture (Basel, Switzerland) and Proquest Investments (Princeton-San Diego, USA). MANAGEMENT FAX +41 (0)91 610 7031 Board of Directors Jean-Philippe Tripet, Aravis, Lombard-Odier Immunology Fund Stuart Holden, MD, Director Cedars-Sinai Prostate Cancer Center Johanna Holldack, MD Behringwerke, Chiron, MediGene, Borean Pharma Alain Schreiber, MD ProQuest, Vical, RhГґnePoulenc t back :: next u YEAR FOUNDED 2007 PRESENTING COMPANIES EMAIL Telormedix@telormedix.com jholldach@telormedix.com Management Team Johanna Holldack, MD, CEO (Behringwerke, Chiron, MediGene, Borean Pharma) Roberto Maj, PharmD, Founder/Head of Drug Development (Pharmacia, Newron, Brane) Alcide Barberis, PhD, Head of Research and Collaborations (ESBATech, Oncalis) Nadia Passini, PhD, Project Management Director (Bioxell, Italfarmaco, Roche) Raffaella Pozzi, PharmD, Head of Clinical Operations (Servier, IBSA ) Filippo Riva, MBA, CFO (Bmob, Waterline, NemeriX, UBS) SUPPORTING ORGANISATIONS ORGANISERS WELCOME TheraKine Ltd www.therakine.com CONTACTS Stan Yakatan CEO Andreas Voigt, PhD CSO MAGNUS Str. 11 12489 Berlin, Germany Private Company Raising $ 2.5 million COMPANY PROFILE TheraKine LTD. Has developed the first in class sustained release, tunable delivery technology for drugs, biological and cosmetics. SPEAKERS ADDRESS 215 33 Rd St Hemosa Beach California 90254 FINANCIAL SUMMARY MANAGEMENT Stan Yakatan, CEO Andreas Voigt, PhD, CSO TELEPHONE 310 374 0808 Office 786 229 9795 Cell YEAR FOUNDED 2009 t back :: next u EMAIL syakatan@aol.com PRESENTING COMPANIES FAX 310 374 0803 SUPPORTING ORGANISATIONS ORGANISERS WELCOME TN LLC www.tncor.com CONTACTS Vladimir Kovalskiy CEO COMPANY PROFILE Dmitry Lazutkin CTO Medesk is the first EMR management company in Russia originally designed and developed for us in the cloud. In addition to the electronic management of medical records, the system allows for the provision of diagnostic services. ADDRESS Moscow, Bersenevskiy per. 5 bld. 4 The purpose of MEDESK is to allow for the maximum freedom from the influence of human factors on the activities and results of medical work. EMAIL request@tncor.com kovalskiy@tncor.com lazutkin@tncor.com The MEDESK technology provides access to features such as patient notification via SMS, remote sensing, sensing of functional and radiographic imaging, automatic calulation of the risk od cardiovascular disease, interaction with contactors and numerous other services. The MEDESK system has all the necessary functions to provide and record all types of outpatient visits for any funding source including non-operating activitites ,and paid services for all categories of people.Thus MEDESK is a complete tool for the clinics. MEDESK came to Sachs looking to expand and devop the platfrom throught out Russia and Europe. MANAGEMENT Vladimir Kovalskiy, CEO Dmitry Lazutkin, CTO PRESENTING COMPANIES Cloud technology allows MEDESK to provide this system to the maximum number of users in the shortest period of time. Using a traditional outsourced service based sales model, the system is percieved as a bargain for the end user as it allows for the insitution to minimize the cost of services. t back :: next u YEAR FOUNDED 2008 SPEAKERS TELEPHONE Vladimir Kovalskiy +79242085076 MEDESK is a privately held medical heath records (EMR) management company that uses its proprietaty system to currently offer its program to in excess of 17 medical clinics in Russia. SUPPORTING ORGANISATIONS ORGANISERS WELCOME uniQure B.V. www.uniqure.com CONTACT JГ¶rn Aldag Chief Executive Officer TELEPHONE + 31 20 566 24 02 FAX +31 20 566 9272 J Aldag, Chief Executive Officer P Morgan, Chief Financial Officer C Meyer, Chief Medical Officer H C Rohde, Chief Commercial Officer H Petry, Research & Development H Preusting, Business Development: t back :: next u YEAR FOUNDED 2012 MANAGEMENT PRESENTING COMPANIES EMAIL info@uniqure.com j.aldag@uniqure.com uniQure is a world leader in the research and early development of human gene based therapies. Its lead product, Glybera, for the treatment of lipoprotein lipase deficiency was approved by the European Commission in November, 2012. Glybera is the first gene therapy approved in the Western world. uniQure has a product pipeline with several gene therapies: for hemophilia B, acute intermittent porphyria, ParkinsonвЂ™s disease and Sanfilippo B. uniQure is based in Amsterdam, the Netherlands. The company employs a staff with extensive scientific and industry experience, and is the world leader in manufacturing of AAV-based products on a commercial scale, meeting cGMP requirements, and has extensive experience in the regulatory process for gene therapies. SPEAKERS ADDRESS Meibergdreef 61 1105 BA Amsterdam The Netherlands COMPANY PROFILE SUPPORTING ORGANISATIONS ORGANISERS WELCOME UroTiss GmbH www. urotiss.com CONTACTS Soeren Liebig CEO Dr Torsten Fahrig CFO The capital requirements of UroTiss for EMA approval are 5.5 million в‚¬. The additional costs for a phase III study in the US for FDA approval are estimated about 4-6 million US$. COMPANY PROFILE UroTiss provides products with highest safety and quality as well as unique specialized urologic Know-How. The companyвЂ™s patented technologies are related to the emerging field of Tissue-Engineering and apply the patientsвЂ™ own cells for the treatment of his urologic diseases. Current indication is urethral stricture. Indications under development include ureteral stricture, hypospadias, oral-maxillofacial-surgery and bladder diseases. SPEAKERS ADDRESS Budapester StraГџe 3 01069 Dresden Germany FINANCIAL SUMMARY We are the first supplier of this kind of therapeutic product worldwide for the treatment of diseased urethra and keep working on the development to treat complex diseases in the field of urogenital system. TELEPHONE +49 (0) 351 43 83 2999 Leading specialized urologic centers use our first product MukoCell in the treatment of urethral stricture. FAX +49 (0) 351 43 83 2997 MANAGEMENT Product MukoCell (Tissue Engineering (TEP) вЂ“ area ATMPs, regenerative medicine), phase III clinical stage. SГ¶ren Liebig, CEO Attorney at law with specialty in Medical Law. YEAR FOUNDED 2005 Dr Torsten Fahrig, CFO Human Medicine, clinical experience in Urology, extensive know-how in Regenerative Medicine. Responsibilities include overseeing Research, Development and Production. Engineer, oversees Finance, Marketing and Operating Business. Many years of experience in Biotechnology/Pharma. Dr JГјrgen Bednarz, Regulatory Affairs & Quality Management Qualified Biologist, many years of experience in Quality Control, Development and Approval of Human Tissues and Tissue Products. PRESENTING COMPANIES Dr Gouya Ram-Liebig, CSO t back :: next u EMAIL info@urotiss.com SUPPORTING ORGANISATIONS ORGANISERS WELCOME Vaccibody AS www.vaccibody.com CONTACT Ole Henrik Brekke Chief Executive Officer FINANCIAL SUMMARY ADDRESS Gaustadalleen 21 0349 Oslo, Norway COMPANY PROFILE FAX +47 2260 4427 EMAIL ohbrekke@vaccibody.com info@vaccibody.com вЂў Vaccibody has a unique vaccine platform targeting dendritic cells in vivo establishing a unique high cellular and antibody responses вЂў A versatile vaccine platform with numerous product opportunities: Many fall-back strategies вЂў Vast market potential from multiple market segments: Risk reduction through planned early partnerships in human infectious and veterinary medicine вЂўH ighly capable team, international network of collaborators, experienced board of directors with a unique technology вЂў Small, flexible and cost efficient organization. MANAGEMENT PRESENTING COMPANIES Dr Ole Henrik Brekke, CEO Dr Agnete Brunsvik Fredriksen, CSO t back :: next u YEAR FOUNDED 2007 вЂў Is seeking 3 Mв‚¬ to take VB 1016 through completion of a Phase-I/IIa study for precancerous lesions. SPEAKERS TELEPHONE +47 2295 8193 Vaccibody is seeking 3 Mв‚¬ to finalize clinical PhaseI/II trial of a therapeutic vaccine against precancerous lesions of the cervix. SUPPORTING ORGANISATIONS ORGANISERS WELCOME Vifor Pharma Ltd www.viforpharma.com CONTACT Dr Roland Pfeiffer Head of Business Development, Europe Susanne Menzi Assistant TELEPHONE +41 58 851 8000 Dr Roland Pfeiffer Tel. +41 58 851 8070 Vifor Pharma generated SFr 633Mn sales in 2012, reflecting above market growth of +8% in local currencies. Prescription products accounted for approximately 65% of sales. Our IV iron products, Ferinject and Venofer, contributed SFr 270Mn. In 2011, our company generated an operational profitability of SFr 254Mn or an operating margin of 43%. The figures for the year ended 2012 will be reported March 12, 2013 along with the Galenica Group full year report. COMPANY PROFILE Vifor Pharma is world market leader in iron replacement therapeutics and oral immunostimulation for the respiratory tract. Vifor is expanding its regional presence beyond our base, Switzerland, and Europe. We operate in France, Germany, Spain, Belgium, Netherlands, Scandinavia, the United Kingdom, Austria, Portugal, Romania, Singapore and Australia. We offer: Co-promotion, fee-for-services etc. to the target groups nephrologists, hematologists, gastro-enterologists, oncologists, gynecologists & hospital-based specialists. Out-licensing in selected territories вЂ“ please inquire. FAX +41 58 851 8001 We are NOT interested in: Generics, OTC, consultancy services PRESENTING COMPANIES We are interested in: Development-stage projects or approved or marketed products in the fields of anemia & iron deficiency, nephrology, gastro-enterology, gynaecology and oncology supportive care throughout the aforementioned territories. t back :: next u Susanne Menzi Tel. +41 58 851 8299 EMAIL roland.pfeiffer@viforpharma.com susanne.menzi@viforpharma.com SPEAKERS ADDRESS Flughofstrasse 61 CH-8152 Glattbrugg FINANCIAL SUMMARY YEAR FOUNDED 1944 SUPPORTING ORGANISATIONS ORGANISERS WELCOME ViroGates www.virogates.com CONTACT Jakob Knudsen Chief Executive Officer COMPANY PROFILE ViroGates A/S is committed to improve the screening and monitoring of patients in a hospital setting and healthy individuals in risk of developing life style related diseases. ViroGates has developed an ELISA (enzyme-linked immunosorbent assay) based suPAR (soluble urokinase Plasminogen Activator Receptor) test that, in clinical settings, has shown to predict mortality and disease progression. More than 120.000 patients have to date been tested with suPARnosticВ®. ViroGates has recently (2013) launched its suPARnostic Quick Triage test based on lateral flow technology. The Quick Triage products provide results in 20 minutes. TELEPHONE +45 22 261 355 ViroGates product portfolio consists of three fully developed products with CE-IVD approvals. The ELISA Standard kit marketed for clinical research and the ELISA Flex kit marketed for routine use at central laboratories in addition to the ELISA products. EMAIL jk@virogates.com YEAR FOUNDED 2001 SPEAKERS ADDRESS Blokken 45 3460 BirkerГёd Denmark Sales and marketing is carried out through ViroGatesвЂ™ network of distributors. ViroGates has more than 20 distribution partners worldwide. MANAGEMENT Jakob Knudsen, Chief Executive Officer PRESENTING COMPANIES t back :: next u SUPPORTING ORGANISATIONS ORGANISERS WELCOME Virometix www.virometix.com CONTACT Dr Arin Ghasparian Chief Executive Officer TELEPHONE +41 44 63 56117 EMAIL info@virometix.com COMPANY PROFILE Virometix AG is an innovative Swiss bio-nanotechnology company that aims to be a leader in the design and development of safe and effective next generation vaccines and nanomedicines. Virometix developed the Synthetic Virus-Like Particle (SVLP) technology, a breakthrough in the bottom-up creation of chemically defined homogenous nano-structures useful for highly efficient vaccine delivery and nanomedicine. Virometix is focusing on: 1. Establishing SVLPs as a safe and effective antigen delivery system for vaccines, and 2. Developing high-value products for chronic non-communicable and emerging infectious diseases. Virometix was founded as a spin-out company from the University of Zurich in October 2009, and is based in Zurich, Switzerland. MANAGEMENT Dr Arin Ghasparian, CEO and co-founder Prof. Klaus Kutz, MD, Chief Development Officer Claudia Dittmar, Chief Business Development Officer t back :: next u Virometix has been awarded by the Swiss confederation two CTI Projects for more than 1 million CHF, enabling financing the R&D of the company until now. Virometix has also obtained seed financing from the Zurcher Kantonalbank and won several business and entrepreneurship prizes, including the W.A. de Vigier Award in 2012. PRESENTING COMPANIES YEAR FOUNDED 2009 Virometix is now seeking financing of at least 2.5 million CHF, and additional financing of at least 7.5 million after first preclinical studies (pharm/tox) have been completed, to develop first vaccine candidates until phase I human clinical trials and diversify its proprietary SVLP nanotechnology platform. SPEAKERS ADDRESS Virometix AG Winterthurerstrasse 190 8057 Zurich Switzerland FINANCIAL SUMMARY SUPPORTING ORGANISATIONS ORGANISERS WELCOME Supporting Organisations BioTOP Berlin-Brandenburg www.biotop.de BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region. SPEAKERS It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster. The services provided by BioTOP include: вЂў Technology transfer science - industry вЂў Initiation and support of networks вЂў Support for technology-oriented start-ups вЂў Funding support for innovative projects вЂў Providing information on biotechnology PRESENTING COMPANIES вЂў Building and coordination of scientific and interdisciplinary networks вЂў Establishing contacts between experts from all disciplines вЂў Design and organization of events вЂў Public relations work for the biotech region Berlin-Brandenburg For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de. t back :: next u Tel: +49 30 318 622 11 Fax + 49 30 318 622 22 SUPPORTING ORGANISATIONS Dr. Kai Bindseil BioTOP Berlin-Brandenburg Fasanenstr. 85 10623 Berlin - Germany ORGANISERS WELCOME Supporting Organisations Citigate Dewe Rogerson www.citigatedr.co.uk Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. SPEAKERS Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the companyвЂ™s overall strength and from the crossfertilisation of ideas across sectors. PRESENTING COMPANIES The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. CitigateвЂ™s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - в‚¬52 million), Algeta (Oslo Stock Exchange - в‚¬30 million), Santhera Pharmaceuticals (SWX вЂ“ CH88.5 million), ThromboGenics (Euronext Brussels - в‚¬35 million), Hutchison China MediTech (AIM - ВЈ40 million), Zentiva (LSE and PSE вЂ“ US $211 million), Arpida (SWX - в‚¬63 million), Inion (LSE - ВЈ35 million), TopoTarget (CSE в‚¬30 million), BioFusion (AIM - ВЈ8.2 million) and ExonHit (Alternext - 7.3 million). t back :: next u Tel: +44 (0)-207-638-9571 SUPPORTING ORGANISATIONS Citigate Dewe Rogerson 3 London Wall Buildings London Wall London EC2M 5SY ORGANISERS WELCOME Supporting Organisations Life Sciences College Hill www.collegehill.com/lifesciences SPEAKERS College Hill Life Sciences provides a full service communications consultancy focused on sciencebased sectors. Within the life science field we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services). London Sue Charles The Registry, Royal Mint Court, London EC3N 4QN, UK T: +44 (0)20 7457 2020 F: +44 (0)20 7866 7900 Email: lsinfo@collegehill.com PRESENTING COMPANIES Manchester Dr Eileen Paul / Chris Fisher Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK Tel: +44 (0)1260 296500 Fax: +44 (0)1260 296501 Email: lsinfo@collegehill.com Munich Dr Robert Mayer AugustenstraГџe 79, 80333 Munich, Germany Tel: +49 (0)89 57 00 18 06 Fax: +49 (0)89 52 38 80 06 Email: lsinfo@collegehill.com t back :: next u SUPPORTING ORGANISATIONS Melbourne Dr Douglas Pretsell Level 9, 278 Collins Street, Melbourne VIC 3000, Australia T: +61 (0)3 9657 0706 Email: lsinfo@collegehill.com ORGANISERS WELCOME Supporting Organisations FreeMind www.freemindconsultants.com SPEAKERS FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMindвЂ™s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen. PRESENTING COMPANIES FreeMindвЂ™s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy. Tel: (617) 648-0340 Fax: (617) 904-1767 Email: info@freemindconsultants.com Boston FreeMind Group 423 Brookline Ave. #124 Boston, MA 02215 SUPPORTING ORGANISATIONS Jerusalem FreeMind Group Hi - Tech Center Hebrew University Jerusalem 95702 Israel t back :: next u Washington DC FreeMind Consultants 4094 Majestic lane # 269 Fairfax, VA 22033 ORGANISERS WELCOME Supporting Organisations Life Science Austria www.lifescienceaustria.at SPEAKERS Life Science Austria - LISA - is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria. Working with all existing life science clusters in the Austrian regions вЂ“ ecoplus, human. technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development. PRESENTING COMPANIES Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ). Tel.: +43 (1) 501 75 - 0 Fax: +43 (1) 501 75 - 900 Email: office@awsg.at Austria Wirtschaftsservice Gesellschaft mbH, Ungargasse 37, 1030 Wien, Austria SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME Supporting Organisations MedNous www.mednous.com MedNous is a print publication and a website for everyone involved in medical research in Europe. The name is derived from the Greek word for knowledge вЂ“ nous вЂ“ and the English word, medical. SPEAKERS The website gathers in one place current news and reference information. Under the heading Research Directory, subscribers can look up past articles from the print publication by title, author, subject and keyword. The print publication analyses complex issues that life science professionals need to understand in order to bring their research into commercial development. These issues relate to regulatory affairs, patent law, government research policy and funding. The print publication appears 10 times per year and includes news, company interviews and commentary by corporate executives and other practicioners in this field. PRESENTING COMPANIES MedNous is well sourced and presented in clear, logical prose. Tel: +44 (0)20 7704 1015 264 Banbury Road Oxford OX2 7DY UK SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME Supporting Organisations Swiss Biotech Association www.swissbiotech.org SwissBiotech вЂ“ One Nation вЂ“ One Biotech Cluster SPEAKERS Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services. The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises SwitzerlandвЂ™s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. PRESENTING COMPANIES Swiss BiotechsвЂ™ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process. Further inquiries: SwissBiotech, Executive Office Tel. +41 (0)44 455 56 78 info@swissbiotech.org SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME Supporting Organisations Tiberend Strategic Advisors, Inc. www.tiberendstrategicadvisors.com SPEAKERS Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies вЂ“ biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies. 1. To enhance valuation 2. To build visibility for partnerships and strategic alliances Tiberend Strategic Advisors, Inc. 35 W. 35th Street, 5th Floor, New York, NY 10001-2205 PRESENTING COMPANIES Tel: 212.827.0020 Fax: 212.827.0028 Fax SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME Supporting Organisations Torreya Partners LLC www.torreyapartners.com SPEAKERS Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco. PRESENTING COMPANIES UK 12 St JamesвЂ™s Square London SW1Y 4LB +44 0207 104 2310 New York 117 East 55th Street New York, NY 10022 (212) 331-7843 SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME Organisers Sachs Associates www.sachsforum.com Sachs Associates is a London based international conference organiser which produces high profile events for the bio-pharmaceutical and financial community. These events are held В In Europe and the USA; currently in Boston and Zurich. The benefits of conference participation with Sachs Associates may be summarised as follows: SPEAKERS The company was established in 1992 and ran emerging growth and emerging market investor forums in association with Dow Jones and then Bloomberg LP over a ten year period. Multimedia Exposure Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the CompanyвЂ™s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies, including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established relationships with other financial press organisations globally, which allow further effective distribution on behalf of its clients. Sponsorship and Marketing Opportunities for forthcoming events Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. The following sponsorship and marketing opportunities are available at future conferences: вЂў Conference Sponsor вЂ“ including workshops and social events вЂў Exhibition stands вЂў Distribution of Promotional Material If your company is interested in exhibiting or sponsorship opportunities please call Zoe Harris on +44 203 463 4890. SUPPORTING ORGANISATIONS Sponsorship of any of our events allows you to raise your companyвЂ™s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events. PRESENTING COMPANIES Eminent Speakers Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted the very senior political and economic personalities as speakers at its events. ORGANISERS S C I E N C E 21-22 May 2013 вЂў The Westin Copley Place вЂў Boston www.sachsforum.com/boston13/index.html 13th Annual Biotech in Europe Investor Forum 30 September вЂ“ 1 October 2013 вЂў Hilton Zurich Airport Hotel вЂў Zurich 27 Belsize Lane London NW3 5AS www.sachsforum.com ORGANISERS Tel: +44 (0) 203 463 4890 Fax: +44 (0) 207 691 7919 SUPPORTING ORGANISATIONS L I F E Annual Cancer Bio Partnering Forum Promoting Public & Private Sector, Collaboration & Investment in Drug Development PRESENTING COMPANIES E U R O P E A N SPEAKERS C E O F O R U M WELCOME We look forward to seeing you at: